Bystander antigen enhancement of tumor cell lysate immunogenicity
Patent Information
- Application Number
- PCT/US2024/019581
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-28
- Filing Date
- 2024-03-12
- Publication Date
- 2024-12-05
AI Technical Summary
Current cancer vaccines face challenges in effectively targeting 'cold tumors' that are poorly immunogenic and lack T cell infiltrates, necessitating tools to enhance the immunogenicity of tumor lysates for personalized cancer therapies.
The use of immunogenic compositions comprising a tumor cell lysate combined with a bystander antigen, a pathogen recognition receptor agonist, and a glycerolipid or phospholipid analog to stimulate an anti-tumor immune response, enhancing the immunogenicity of tumor lysates and inducing T cell responses.
This approach significantly enhances tumor-specific T cell responses and immune activation, leading to improved anti-tumor immunity and prolonged survival in mouse models with LLC1 and B16-F10 tumors, demonstrating the potential for effective cancer immunotherapy.
Smart Images

Figure US2024019581_05122024_PF_FP_ABST
Abstract
Description
Docket No.: 16553-20009.40 BYSTANDER ANTIGEN ENHANCEMENT OF TUMOR CELL LYSATE IMMUNOGENICITY CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and benefit of U.S. Provisional Patent Application No.63 / 523,870, filed June 28, 2023, and U.S. Provisional Patent Application No. 63 / 451,879, filed March 13, 2023, each of which is incorporated herein by reference in its entirety. REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[0002] The content of the electronic sequence listing (165532000940SEQLIST.xml; Size: 6,781 bytes; and Date of Creation: March 6, 2024) is incorporated herein by reference in its entirety. FIELD
[0003] The present disclosure relates to immunogenic compositions comprising a tumor cell lysate and a bystander antigen, and uses thereof in stimulating an anti-tumor immune response in a mammalian subject. The present disclosure also relates to compositions comprising a tumor cell lysate, a bystander antigen, and one or both of a pathogen recognition receptor agonist, and a glycerolipid or phospholipid analog. BACKGROUND
[0004] The goal of therapeutic cancer vaccines is to establish an immune response against cancer cells that is sufficiently potent to cause tumor regression or at least impede tumor growth. Since tumors occur through accumulation of genetic mutations and epigenetic alterations, which not shared by all cancer patients, cancer vaccines must be personalized to some extent. One way to produce personalized cancer vaccines is to utilize cancerous tissue from a subject as a source of relevant tumor antigens. However, some tumors are poorly immunogenic (“cold tumors”) and are largely devoid of T cell infiltrates (Bonaventura et al., Frontiers in Immunology, 10:article 168, 2019).
[0005] Thus, what is needed in the art are tools for enhancing the immunogenicity of tumor lysates, particularly tumor lysates prepared from immunologically cold tumors.sf-5700344Docket No.: 16553-20009.40 BRIEF SUMMARY
[0006] The present disclosure relates to immunogenic compositions comprising a tumor cell lysate and a bystander antigen, and uses thereof in stimulating an anti-tumor immune response in a mammalian subject. The present disclosure also relates to compositions comprising a tumor cell lysate, a bystander antigen, and one or both of a pathogen recognition receptor agonist, and a glycerolipid or phospholipid analog. BRIEF DESCRIPTION OF THE DRAWINGS
[0007] FIG.1A shows a timeline for immunization of mice bearing LLC1-originated tumors and a survival curve for mice in the three treatment groups. All mice were immunized and boosted with a whole tumor lysate (WTL) prepared from LLC1 tumors in the presence or absence of a hyperactivating stimulus, the TLR7 / 8 agonist R848 plus the glycerolipid 22:lysoPC, in the presence or absence of a bystander antigen (ovalbumin). FIG. 1B is a plot showing tumor size over time of the immunized mice.
[0008] FIG.2 shows IL-1beta secretion by murine bone marrow-derived dendritic cells (BMDCs) cultured in the presence or absence of a hyperactivating stimulus (R848 plus the 22:lysoPC) and in the presence or absence of varying amounts of bystander antigen (ovalbumin or bovine serum albumin).
[0009] FIG.3A shows a timeline for immunization of mice bearing LLC1-originated tumors and a survival curve for mice in the three treatment groups. All mice were immunized and boosted with a whole tumor lysate (WTL) prepared from LLC1 tumors in the presence or absence of a hyperactivating stimulus, the TLR7 / 8 agonist R848 plus the glycerolipid 1 docosyl- sn-glycerol-3-phosphate (DGP), in the presence or absence of a bystander antigen (COVID-19 spike protein). FIG.3B is a plot showing tumor size over time of the immunized mice.
[0010] FIG.4A-4B show that inclusion of a bystander antigen (COVID-19 spike protein) in an immunogenic composition comprising a hyperactivating stimulus and a whole tumor lysate (WTL) enhances tumor-specific T cell responses. CD4+ and CD8+ T cells isolated from draining lymph nodes of survivor mice were co-cultured with naïve DCs loaded (or not) with WTL or COVID-19 spike protein to assess antigen-specific T cell responses. Mice immunized with a composition comprising both WTL and COVID-19 spike protein induced 2sf-5700344Docket No.: 16553-20009.40 higher IFN-gamma responses when CD8+ T cells (FIG.4A) or CD4+ T cells (FIG.4B) were restimulated in vitro in the presence of DCs loaded with WTL.
[0011] FIG.5 shows a timeline for immunization of mice bearing B16-F10- originated tumors and a survival curve for mice in the four treatment groups. All mice were immunized and boosted with a whole tumor lysate (WTL) prepared from LLC1 tumors in the presence or absence of a hyperactivating stimulus, the TLR7 / 8 agonist R848 plus the glycerolipid 22:lysoPC, in the presence or absence of a bystander antigen (ovalbumin).
[0012] FIG.6A-6B show that immunogenic compositions comprising a hyperactivating stimulus, a whole tumor lysate (WTL) and a bystander antigen (Spike) induce T- cell responses to both the WTL (FIG.6A) and the bystander antigen (FIG. 6B) as determined by measuring interferon-gamma secretion upon restimulation of splenocytes from immunized mice. DETAILED DESCRIPTION
[0013] The present disclosure relates to immunogenic compositions comprising a tumor cell lysate and a bystander antigen, and uses thereof in stimulating an anti-tumor immune response in a mammalian subject. The present disclosure also relates to compositions comprising a tumor cell lysate, a bystander antigen, and one or both of a pathogen recognition receptor agonist, and a glycerolipid or phospholipid analog. General Techniques and Definitions
[0014] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art.
[0015] As used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural references unless indicated otherwise. For example, “an” excipient includes one or more excipients.
[0016] The phrase “comprising” as used herein is open-ended, indicating that such embodiments may include additional elements. In contrast, the phrase “consisting of” is closed, indicating that such embodiments do not include additional elements (except for trace impurities). The phrase “consisting essentially of” is partially closed, indicating that suchsf-5700344Docket No.: 16553-20009.40 embodiments may further comprise elements that do not materially change the basic characteristics of such embodiments.
[0017] The term “about” as used herein in reference to a value, encompasses from 90% to 110% of that value (e.g., a molecular weight of about 900 daltons, refers to a molecular weight of from 810 daltons to 990 daltons).
[0018] An “effective amount” or a “sufficient amount” of a substance is that amount sufficient to effect beneficial or desired results, including clinical results, and, as such, an “effective amount” depends upon the context in which it is being applied. For instance, in the context of administering an immunogenic composition, an effective amount contains sufficient antigen, and one or both of a lysophosphatidylcholine (LPC) compound and a PRR agonist, to stimulate an immune response against the antigen (e.g., antigen-reactive antibody and / or cellular immune response).
[0019] The terms “individual” and “subject” refer to mammals. “Mammals” include, but are not limited to, humans, non-human primates (e.g., monkeys), farm animals, sport animals, rodents (e.g., mice and rats), and pets (e.g., dogs and cats). In some embodiments, the subject is a human patient, such as a human patient suffering from cancer and / or an infectious disease.
[0020] The term “dose” as used herein in reference to an immunogenic composition refers to a measured portion of the immunogenic composition taken by (administered to or received by) a subject at any one time.
[0021] The terms “isolated” and “purified” as used herein refers to a material that is removed from at least one component with which it is naturally associated (e.g., removed from its original environment). As an example, when used in reference to an LPC, an isolated LPC is at least 90%, 95%, 96%, 97%, 98% or 99% pure as determined by thin layer chromatography, or gas chromatography. As a further example, when used in reference to a recombinant protein, an isolated protein refers to a protein that has been removed from the culture medium of the host cell that produced the protein. As a still further example, when used in reference to a bystander antigen, an “isolated bystander antigen” refers to an antigen (polypeptide) that is at least 90%, 95%, 96%, 97%, 98% or 99% pure as determined by SDS-PAGE.sf-5700344Docket No.: 16553-20009.40
[0022] The terms “pharmaceutical formulation” and “pharmaceutical composition” refer to preparations that are in such form as to permit the biological activity of the active ingredient to be effective, and that contain no additional components that are unacceptably toxic to an individual to which the formulation or composition would be administered. Such formulations or compositions are intended to be sterile.
[0023] “Excipients” as used herein include pharmaceutically acceptable excipients, carriers, vehicles or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable excipient is an aqueous pH buffered solution.
[0024] The term “antigen” refers to a substance that is recognized and bound specifically by an antibody or by a T cell antigen receptor. Antigens can include peptides, polypeptides, proteins, glycoproteins, polysaccharides, complex carbohydrates, sugars, gangliosides, lipids and phospholipids; portions thereof and combinations thereof. Antigens when present in the compositions of the present disclosure can be synthetic or isolated from nature. Antigens suitable for administration in the methods of the present disclosure include any molecule capable of eliciting an antigen-specific B cell or T cell response. Haptens are included within the scope of “antigen.” A “hapten” is a low molecular weight compound that is not immunogenic by itself but is rendered immunogenic when conjugated with a generally larger immunogenic molecule (carrier).
[0025] As used herein, the term “lysis” refers to the disruption of a cell’s membrane, and the term “tumor cell lysate” refers to a preparation containing the contents of lysed tumor cells. A “tumor cell lysate” may be a “whole tumor lysate” in which cells of the tumor have not been subject to positive or negative enrichment of specific cell populations that may be present in the tumor in vivo (e.g., tumor biopsy sample not subjected to leukocyte depletion before lysis). Tumor cell lysis can be accomplished by mechanical (e.g., freeze thaw cycle), enzymatic (e.g., lysozyme), and / or other means.
[0026] “Polypeptide antigens” can include purified native peptides, synthetic peptides, recombinant peptides, crude peptide extracts, or peptides in a partially purified or unpurified active state (such as peptides that are part of attenuated or inactivated viruses, 5sf-5700344Docket No.: 16553-20009.40 microorganisms or cells), or fragments of such peptides. Polypeptide antigens are preferably at least eight amino acid residues in length, preferably at least twenty amino acid residues in length.
[0027] The term “agonist” is used in the broadest sense and includes any molecule that activates signaling through a receptor. In some embodiments, the agonist binds to the receptor. For instance, a TLR8 agonist binds to a TLR8 receptor and activates a TLR8-signaling pathway.
[0028] “Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groups. Cx alkyl refers to an alkyl group having x number of carbon atoms. Cx-Cy alkyl or Cx-y alkyl refers to an alkyl group having between x number and y number of carbon atoms, inclusive.
[0029] “Alkylene” refers to divalent saturated aliphatic hydrocarbyl groups.
[0030] “Alkenyl” refers to monovalent hydrocarbyl groups having at least one double bond (>C=C<). Cx alkenyl refers to an alkenyl group having x number of carbon atoms. Cx-Cy alkenyl or Cx-y alkenyl refers to an alkenyl group having between x number and y number of carbon atoms, inclusive.
[0031] “Stimulation” of a response or parameter includes eliciting and / or enhancing that response or parameter when compared to otherwise same conditions except for a parameter of interest, or alternatively, as compared to another condition (e.g., increase in TLR-signaling in the presence of a TLR agonist as compared to the absence of the TLR agonist). For example, “stimulation” of an immune response means an increase in the response. Depending upon the parameter measured, the increase may be from 2-fold to 2,000-fold, or from 5-fold to 500-fold or over, or from 2, 5, 10, 50, or 100-fold to 500, 1,000, 2,000, 5,000, or 10,000-fold.
[0032] Conversely, “inhibition” of a response or parameter includes reducing and / or repressing that response or parameter when compared to otherwise same conditions except for a parameter of interest, or alternatively, as compared to another condition (e.g., decrease in abnormal cell proliferation after administration of a composition comprising a LPC compound and one or more of a pathogen recognition receptor agonist, an antigen, and human dendritic cells, as compared to the administration of a placebo composition or no treatment). For example, “inhibition” of an immune response means a decrease in the response. Depending upon thesf-5700344Docket No.: 16553-20009.40 parameter measured, the decrease may be from 2-fold to 2,000-fold, or from 5-fold to 500-fold or over, or from 2, 5, 10, 50, or 100-fold to 500, 1,000, 2,000, 5,000, or 10,000-fold.
[0033] The relative terms “higher” and “lower” refer to a measurable increase or decrease, respectively, in a response or parameter when compared to otherwise same conditions except for a parameter of interest, or alternatively, as compared to another condition. For instance, a “higher level of DC hyperactivation” refers to a level of DC hyperactivation as a consequence of a treatment condition (comprising a LPC compound of the present disclosure) that is at least 2, 3, 4, 5, 6, 7, 8, 9, or 10-fold above a level of DC hyperactivation as a consequence of a control condition (e.g., no LPC, PGPC, oxPAPC, etc.). Likewise, a “lower level of DC hyperactivation” refers to a level of DC hyperactivation as a consequence of a treatment condition (comprising a LPC compound of the present disclosure) that is at least 2, 3, 4, 5, 6, 7, 8, 9, or 10-fold below a level of DC hyperactivation as a consequence of a control condition (e.g., no LPC, PGPC, oxPAPC, etc.).
[0034] As used herein the term “immunization” refers to a process that increases a mammalian subject’s reaction to antigen and therefore improves its ability to resist or overcome infection and / or resist disease.
[0035] The term “vaccination” as used herein refers to the introduction of vaccine into a body of a mammalian subject.
[0036] “Adjuvant” refers to a substance which, when added to a composition comprising an antigen, enhances or potentiates an immune response to the antigen in the mammalian recipient upon exposure.
[0037] The terms “treating” or “treatment” of a disease refer to executing a protocol, which may include administering one or more therapeutic agents to an individual (human or otherwise), in an effort to obtain beneficial or desired results in the individual, including clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more signs or symptoms of a disease, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total). “Treatment” also can mean prolonging survival as compared to expected survival of ansf-5700344Docket No.: 16553-20009.40 individual not receiving treatment. Further, “treating” and “treatment” may occur by administration of one dose of a therapeutic agent or therapeutic agents, or may occur upon administration of a series of doses of a therapeutic agent or therapeutic agents. “Treating” or “treatment” does not require complete alleviation of signs or symptoms, and does not require a cure, and specifically includes protocols that have only a palliative effect on the individual. “Palliating” a disease or disorder means that the extent and / or undesirable clinical manifestations of the disease or disorder are lessened and / or time course of progression of the disease or disorder is slowed, as compared to the expected untreated outcome. I. Bystander Antigens
[0038] Compositions and methods of the present disclosure comprise a bystander antigen. As used herein, the term “bystander antigen” refers to a polypeptide that is heterologous to a mammalian subject who is the intended recipient of an immunogenic composition comprising the bystander antigen. That is, the bystander antigen is foreign (non-self) in relation to the intended recipient. In preferred embodiments, the bystander antigen is an isolated bystander antigen that is at least 90% pure. Preferably the isolated bystander antigen is least 95% pure. More preferably, the isolated bystander antigen is at least 98% pure. As such, the isolated bystander antigen is substantially free of self antigens (e.g., fragments of the bystander antigen are not bound to MHC class II molecules expressed by tumor cells).
[0039] In preferred embodiments, the bystander antigen comprises a polypeptide whose amino acid sequence corresponds to a protein or fragment thereof of different species, preferably of a different genus, preferably of a different family, preferably of a different order, preferably of a different class, preferably of a different phylum, preferably of a different kingdom, or preferably of a different domain, than the intended recipient. For instance, in Example 1, the recipients of the immunogenic compositions comprising ovalbumin (OVA of Gallus gallus) or bovine serum albumin (BSA of Bos taurus) as the bystander antigen were mice (Mus musculus). Thus, the exemplary bystander antigen OVA is a polypeptide whose amino acid sequence corresponds to a protein of a different, species, genus, family, order, and class than the murine recipient. Similarly, the exemplary bystander antigen BSA is a polypeptide whose amino acid sequence corresponds to a protein of a different, species, genus, family, and order than the murine recipient. Accordingly, in some embodiments, the bystander antigen comprises asf-5700344Docket No.: 16553-20009.40 polypeptide or fragment thereof of mammalian antigen, an avian antigen, a reptilian antigen, or an amphibian antigen.
[0040] In some embodiments, the bystander antigen comprises a polypeptide or fragment thereof of a microbial antigen. In some embodiments, the microbial antigen comprises a surface protein or other antigenic subunit of a microbe. In other embodiments, the microbial antigen comprises an inactivated or attenuated microbe. For instance, the microbial antigen may comprise an inactivated virus, such as a chemically or genetically-inactivated virus. Alternatively, the microbial antigen may comprise a virus-like particle. The microbial antigen may comprise one or more of a viral antigen, a bacterial antigen, a protozoan antigen, and a fungal antigen. In some embodiments, the bystander antigen comprises a polypeptide whose amino acid sequence corresponds to a protein or fragment thereof of a non-cellular life form, such as a virus (e.g., SARS-CoV-2 spike protein). As such, in some embodiments, the bystander antigen comprises a polypeptide or fragment thereof of a viral antigen.
[0041] The terms “polypeptide” and “protein” are used interchangeably herein to refer to proteinaceous antigens that comprise peptide chains that are at least 8 amino acids in length. In some embodiments, the polypeptide is from about 8 to about 8000 amino acids in length, preferably from about 20 to about 2000 amino acids in length, preferably from about 30 to about 1700 amino acids in length, preferably from about 40 to about 1600 amino acids in length, preferably from about 50 to about 1500 amino acids length, preferably from about 60 to about 1400 amino acids length, preferably from about 70 to about 1300 amino acids length, preferably from about 80 to about 1200 amino acids length, preferably from about 90 to about 1100 amino acids length, or preferably from about 100 to about 1000 amino acids length. In certain embodiments, the polypeptide is greater than 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 amino acids in length, and less than 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000, or 1000 amino acids in length. In certain embodiments, the polypeptide is from about 20 to about 2000 amino acids in length.
[0042] In some embodiments, the antigen is a synthetic polypeptide. In other embodiments, the antigen is a recombinant polypeptide. In further embodiments, the antigen comprises is a native polypeptide (e.g., non-recombinant polypeptide), which may be purifiedsf-5700344Docket No.: 16553-20009.40 from a biological sample. The polypeptide may be post-translationally modified such as by phosphorylation, hydroxylation, sulfonation, palmitoylation, and / or glycosylation.
[0043] In some embodiments, the bystander antigen is a “recall antigen” that has been previously encountered by the mammalian subject, and thus the subject possesses pre- existing, bystander antigen-reactive, memory lymphocytes. For instance, the recall antigen may be an antigen to which the subject was exposed as part of a standard childhood or adult immunization scheme (e.g., SARS-CoV-2 spike protein). In other embodiments, the bystander antigen is an “unfamiliar antigen” that has not been previously encountered by the mammalian subject, and thus the subject does not possess pre-existing, bystander antigen-reactive, memory lymphocytes. For instance, the recall antigen may be an antigen to which the subject was not exposed as part of a standard childhood or adult immunization scheme (e.g., chicken egg white ovalbumin). II. Lipid Compounds
[0044] Compositions and methods of the present disclosure may comprise a hyperactivating lipid. In preferred embodiments, the lipid is a glycerolipid or a phospholipid analog. Glycerolipids suitable for use in the compositions and methods of the present disclosure include lysophosphatidylcholine compounds and ether lipids. A. Lysophosphatidylcholine Compounds
[0045] As used herein, the terms “lysophosphatidylcholine” and “lysophosphatidylcholine molecule” refer to a glycerol molecule bearing one phosphocholine group on a hydroxyl group of the glycerol and bearing one acyl group on one of the other two hydroxyl groups of the glycerol. The remaining hydroxyl group is unsubstituted. In some embodiments, the lysophosphatidylcholine compound is not a lysolecithin.
[0046] In some embodiments, the isolated lysophosphatidylcholine (LPC) with a single acyl chain is of the form:sf-5700344Docket No.: 16553-20009.40 or.
[0047] In some embodiments, the isolated lysophosphatidylcholine (LPC) with a single acyl chain is of the form:.
[0048] The alkyl or alkenyl chain, together with the carbonyl carbon, forms an acyl chain which is one carbon atom longer than the alkyl or alkenyl chain. For example, a (C23 alkyl)-C(=O)- group forms a C24 acyl chain. Thus, when the group “(alkyl or alkylene)” is a C12-C23 alkyl group (such as a C12-C19 alkyl group or a C20-C23 alkyl group), the (C12-C23 alkyl-C(=O)- group forms a C13-C24 acyl chain (such as a C13-C20 acyl chain or a C21-C24 acyl chain). When the group “(alkyl or alkylene)” is a C12-C23 alkenyl group (such as a C12-sf-5700344Docket No.: 16553-20009.40 C19 alkenyl group or a C20-C23 alkenyl group), the (C12-C23 alkenyl-C(=O)- group forms a C13-C24 acyl chain (such as a C13-C20 acyl chain or a C21-C24 acyl chain). Acyl chains can be referred to as saturated acyl or unsaturated acyl to distinguish between alkyl-containing and alkenyl-containing acyl groups. Standard delta notation or omega notation can be used to indicate the position of one or more double bonds in an unsaturated acyl chain.
[0049] Lysophosphatidylcholine (LPC) compounds of the present disclosure have a single acyl chain in which the acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain. In some embodiments, the acyl chain is a C18-C22 acyl chain, a C19-C23 acyl chain, or a C21-C24 acyl chain. In some embodiments, the acyl chain is a C19-C22 acyl chain. In some embodiments, the acyl chain is a C19 acyl chain. In some embodiments, the acyl chain is a C20 acyl chain. In some embodiments, the acyl chain is a C21 acyl chain. In some preferred embodiments, the acyl chain is a C22 acyl chain. In some embodiments, the acyl chain is a C21 acyl chain or a C22 acyl chain. In some preferred embodiments, the acyl chain is fully saturated.
[0050] Names and structures of exemplary LPC compounds of the present disclosure, as well as their Chemical Abstract Service (CAS) Registry Numbers are shown in Table I below. In some preferred embodiments, the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3- phosphocholine [LPC(22:0)]. In other embodiments, the LPC comprises a species of oxidized l- palmitoyl-2-arachidonoyl- sn-glycero-3-phosphorylcholine (oxPAPC). In some embodiments, the species of oxPAPC comprises 2-[[(2R)-2-[(E)-7-carboxy-5-hydroxyhept-6- enoyl]oxy-3- hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium (HOdiA-PC), [(2R)- 2-[(E)-7-carboxy-5-oxohept-6-enoyl]oxy-3-hexadecanoyloxypropyl] 2- (trimethylazaniumyl)ethyl phosphate (KOdiA-PC), l-palmitoyl-2-(5-hydroxy-8-oxo- octenoyl)- sn-glycero-3-phosphorylcholine (HOOA-PC), 2-[[(2R)-2-[(E)-5,8-dioxooct-6- enoyl]oxy-3- hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium (KOOA-PC), [(2R)- 3-hexadecanoyloxy-2-(5-oxopentanoyloxy)propyl] 2- (trimethylazaniumyl)ethyl phosphate (POVPC), [(2R)-2-(4-carboxybutanoyloxy)-3- hexadecanoyloxypropyl] 2- (trimethylazaniumyl)ethyl phosphate (PGPC), [(2R)-3- hexadecanoyloxy-2-[4-[3-[(E)-[2-[(Z)- oct-2-enyl]-5-oxocyclopent-3-en-l- ylidene]methyl]oxiran-2-yl]butanoyloxy]propyl] 2- (trimethylazaniumyl)ethyl phosphate (PECPC), [(2R)-3-hexadecanoyloxy-2-[4-[3-[(E)-[3- hydroxy-2-[(Z)-oct-2-enyl]-5- oxocyclopentylidene]methyl]oxiran-2-yl]butanoyloxy]propyl] 2-sf-5700344Docket No.: 16553-20009.40 (trimethylazaniumyl)ethyl phosphate (PEIPC), or a combination thereof. In some preferred embodiments, the LPC comprises [(2R)-2-(4-carboxybutanoyloxy)-3- hexadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate (PGPC). Table I. Exemplary Lysophosphatidylcholine (LPC) Compoundssf-5700344Docket No.: 16553-20009.40sf-5700344Docket No.: 16553-20009.40sf-5700344Docket No.: 16553-20009.40 B. Ether Lipid (ETL) Compounds
[0051] The terms “ether lipid” (ETL) and “ether lipid molecule” as used herein, refer to a glycerol molecule bearing a hydrocarbyl group on one of the hydroxyl groups of the glycerol. The remaining hydroxyl groups can be unsubstituted (free hydroxyl groups) or can be substituted. The hydrocarbyl group can be an aliphatic hydrocarbyl group, such as an alkyl group, such as an n-alkyl group.
[0052] An “ether phospholipid” (ETPL) or “ether phospholipid molecule” is a particular type of ether lipid, and refers to a glycerol molecule bearing a phosphate group on a hydroxyl of the glycerol and bearing one hydrocarbyl group on one of the other two hydroxyl groups of the glycerol. The remaining hydroxyl group can be unsubstituted (a free hydroxyl group) or can be substituted. The hydrocarbyl group can be an aliphatic hydrocarbyl group, such as an alkyl group, such as an n-alkyl group. In some embodiments, the hydrocarbyl group is a C18-C22 alkyl group. In some embodiments, the hydrocarbyl group is a C22 alkyl group. In other embodiments, the hydrocarbyl group is a C18 alkyl group.
[0053] In some embodiments, the ether lipid is a compound of Formula (I), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (I):sf-5700344Docket No.: 16553-20009.40 each R5is independently C1-C4alkyl; or a protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof; and all stereoisomers thereof.
[0054] In some embodiments, provided herein are ether lipid compounds of Formula (II), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (II):each R5is independently C1-C4alkyl; or a protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof.
[0055] In some embodiments, provided herein are ether lipid compounds of Formula (III), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (III):sf-5700344Docket No.: 16553-20009.40 where R2is H, C1-C4alkyl,C6H5; R3is C13-C24n-alkyl; and each R5is independently C1-C4 alkyl; or a salt thereof, such as a pharmaceutically acceptable salt thereof.
[0056] In some embodiments, provided herein are ether lipid compounds of Formula (III-A), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (III-A):R3is C13-C24n-alkyl; and each R5is independently C1-C4alkyl; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, some embodiments, R2is -(C=O)-NH-CH3. In some embodiments, In some embodiments, R3is C21-C24n-alkyl. In some embodiments,R3is C21-C24n-alkyl. In some embodiments, R2is -(C=O)-NH-CH3and R3is C21-C24n-alkyl. In some embodiments, R2is -(C=O)-N(CH3)2and R3is C21-C24n-alkyl. In some embodiments, R2is -(C=O)-NH2and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-NH-CH3and R3is C22n-alkyl. In some embodiments, R2is -(C=O)- N(CH3)2and R3is C22n-alkyl.
[0057] In some embodiments, provided herein are ether lipid compounds of Formula (III-A-1), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (III-A-1):sf-5700344Docket No.: 16553-20009.40R3is C21-C24n-alkyl; and each R5is independently C1-C4alkyl; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R2is -(C=O)-NH2. In some embodiments, R2is -(C=O)-NH-CH3. In some embodiments, R2is -(C=O)-N(CH3)2. In some embodiments, R3is C22n-alkyl. In some embodiments, R2is -(C=O)-NH2and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-NH-CH3and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-N(CH3)2and R3is C22n-alkyl.
[0058] In some embodiments, provided herein are ether lipid compounds of Formula (III-A-2), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (III-A-2):R3is C16-C20n-alkyl; and each R5is independently C1-C4alkyl; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R2is -(C=O)-NH2. In some embodiments, R2is -(C=O)-NH-CH3. In some embodiments, R2is -(C=O)-N(CH3)2. In some embodiments, R3is C18n-alkyl. In some embodiments, R2is -(C=O)-NH2and R3is C18n-alkyl. In some embodiments, R2sf-5700344Docket No.: 16553-20009.40 is -(C=O)-NH-CH3and R3is C18n-alkyl. In some embodiments, R2is -(C=O)-N(CH3)2and R3is C18n-alkyl.
[0059] In some embodiments, provided herein are ether lipid compounds of Formula (III-B), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (III-B):Formula (III-B) where R3is C13-C24 n-alkyl; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R3is C21-C24n-alkyl. In some embodiments, R3is C22n-alkyl.
[0060] In some embodiments, provided herein are ether lipid compounds of Formula (III-B-1), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (III-B-1):Formula (III-B-1) where R3is C21-C24n-alkyl; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R3is C22n-alkyl.
[0061] In some embodiments, provided herein are ether lipid compounds of Formula (III-B-2), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (III-B-2):sf-5700344Docket No.: 16553-20009.40Formula (III-B-2) where R3is C16-C20n-alkyl; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R3is C18n-alkyl.
[0062] In some embodiments, provided herein are ether lipid compounds of Formula (IV), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV):each R5is independently C1-C4alkyl; or a protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof.
[0063] In some embodiments, provided herein are ether lipid compounds of Formula (IV-A), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-A):sf-5700344Docket No.: 16553-20009.40Formula (IV-A) where R2is H, C1-C4alkyl, -(C=O)-NH2, -(C=O)-NH(R5) , -(C=O)-N(R5)2, or -CH2-C6H5; R3is C13-C24n-alkyl; and each R5is independently C1-C4alkyl; or a protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R2is H. In some embodiments, R2is -(C=O)- NH2. In some embodiments, R2is -(C=O)-NH-CH3. In some embodiments, R2isN(CH3)2. In some embodiments, R3is C21-C24n-alkyl. In some embodiments, R2is H and R3is C21-C24n-alkyl. In some embodiments, R2is -(C=O)-NH2and R3is C21-C24n-alkyl. In some embodiments, R2is -(C=O)-NH-CH3and R3is C21-C24n-alkyl. In some embodiments, R2is -(C=O)-N(CH3)2and R3is C21-C24n-alkyl. In some embodiments, R2is H and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-NH2and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-NH-CH3and R3is C22n-alkyl. In some embodiments, R2is -(C=O)- N(CH3)2and R3is C22n-alkyl.
[0064] In some embodiments, provided herein are ether lipid compounds of Formula (IV-A-1), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-A-1):sf-5700344Docket No.: 16553-20009.40 where R2is H, C1-C4alkyl,or -CH2-C6H5; R3is C21-C24n-alkyl; and each R5is independently C1-C4 alkyl; or a protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R2is H. In some embodiments, R2is -(C=O)- NH2. In some embodiments, R2is -(C=O)-NH-CH3. In some embodiments, R2is -(C=O)- N(CH3)2. In some embodiments, R3is C22n-alkyl. In some embodiments, R2is H and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-NH2and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-NH-CH3and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-N(CH3)2and R3is C22n-alkyl.
[0065] In some embodiments, provided herein are ether lipid compounds of Formula (IV-A-2), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-A-2):Formula (IV-A-2) where R2is H, C1-C4alkyl, -(C=O)-NH2, -(C=O)-NH(R5) , -(C=O)-N(R5)2, or -CH2-C6H5; R3is C16-C20n-alkyl; and each R5is independently C1-C4 alkyl; or a protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R2is H. In some embodiments, R2is -(C=O)- NH2. In some embodiments, R2is -(C=O)-NH-CH3. In some embodiments, R2is -(C=O)- N(CH3)2. In some embodiments, R3is C18n-alkyl. In some embodiments, R2is H and R3is C18n-alkyl. In some embodiments, R2is -(C=O)-NH2and R3is C18n-alkyl. In some embodiments,sf-5700344Docket No.: 16553-20009.40 R2is -(C=O)-NH-CH3and R3is C18n-alkyl. In some embodiments, R2is -(C=O)-N(CH3)2and R3is C18n-alkyl.
[0066] In some embodiments, provided herein are ether lipid compounds of Formula (IV-B), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-B):Formula (IV-B) where R2is H, C1-C4alkyl,or -CH2-C6H5; R3is C13-C24n-alkyl; and each R5is independently C1-C4alkyl; or a protonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof.
[0067] In some embodiments, provided herein are ether lipid compounds of Formula (IV-B-1), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-B-1):Formula (IV-B-1) where R2is H, C1-C4alkyl, -(C=O)-NH2, -(C=O)-NH(R5) , -(C=O)-N(R5)2, or -CH2-C6H5;sf-5700344Docket No.: 16553-20009.40 R3is C21-C24n-alkyl; and each R5is independently C1-C4alkyl; or a protonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R2is H. In some embodiments, R2is -(C=O)-NH2. In some embodiments, R2is -(C=O)-NH-CH3. In some embodiments, R2is -(C=O)-N(CH3)2. In some embodiments, R3is C22n-alkyl. In some embodiments, R2is H and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-NH2and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-NH-CH3and R3is C22n-alkyl. In some embodiments, R2is -(C=O)-N(CH3)2and R3is C22n-alkyl.
[0068] In some embodiments, provided herein are ether lipid compounds of Formula (IV-B-2), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-B-2):or -CH2-C6H5; R3is C16-C20n-alkyl; and each R5is independently C1-C4alkyl; or a protonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R2is H. In some embodiments, R2is -(C=O)-NH2. In some embodiments, R2is -(C=O)-NH-CH3. In some embodiments, R2is -(C=O)-N(CH3)2. In some embodiments, R3is C18n-alkyl. In some embodiments, R2is H and R3is C18n-alkyl. In some embodiments, R2is -(C=O)-NH2and R3is C18n-alkyl. In some embodiments, R2is -(C=O)-NH-CH3and R3is C18n-alkyl. In some embodiments, R2is -(C=O)-N(CH3)2and R3is C18n-alkyl.sf-5700344Docket No.: 16553-20009.40
[0069] In some embodiments, provided herein are ether lipid compounds of Formula (IV-C), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-C):Formula (IV-C) where R3is C13-C24n-alkyl; andor a protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof.
[0070] In some embodiments, provided herein are ether lipid compounds of Formula (IV-D), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-D):Formula (IV-D) where R3is C13-C24n-alkyl; or a protonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R3is C16-C20n-alkyl. In some embodiments, R3is C21-C24n- alkyl. In some embodiments, R3is C22n-alkyl.sf-5700344Docket No.: 16553-20009.40
[0071] In some embodiments, provided herein are ether lipid compounds of Formula (IV-E), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-E):Formula (IV-E) where R3is C13-C24n-alkyl; or a protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof. In some embodiments, R3is C21-C24n-alkyl.
[0072] In some embodiments, provided herein are ether lipid compounds of Formula (IV-F), such as an isolated ether phospholipid (ETPL) with an alkyl chain of Formula (IV-F):whereinalkyl; or a or or a salt thereof. In some embodiments, R2is H. In some embodiments, R2is -(C=O)-NH2. In some embodiments, R2is -(C=O)-NH(R5) . In some embodiments, R2is -(C=O)-N(R5)2. In some embodiments, R3is C21n-alkyl. In some embodiments, R3is unsubstituted. In somesf-5700344Docket No.: 16553-20009.40 embodiments, R5is -CH3. Formula (IV-F) is a combination of certain compounds of Formula (IV-A) and Formula (IV-E).
[0073] In some embodiments, provided herein are ether lipid compounds of Formula (A), such as an isolated ether lipid (ETL) with an alkyl chain of Formula (I):each R5is independently C1-C4alkyl; or a protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof; and all stereoisomers thereof.
[0074] In some embodiments, the ether phospholipid (ETPL) with an n-alkyl chain is a compound of Formula (IV), where R4is (CH3)3N+-(CH2)2- ; R2is H; R3is C22n-alkyl, and the compound is 1-docosyl-sn-glycerol-3-phosphocholine (DGPC):; or a protonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof.
[0075] In some embodiments, the ether phospholipid (ETPL) with an n-alkyl chain is a compound of Formula (IV), where R4is H ; R2is H ; R3is C22n-alkyl, and the compound is 1-docosyl-sn-glycerol-3-phosphate (DGP):sf-5700344Docket No.: 16553-20009.40protonated or deprotonated form thereof; or a salt thereof, such as a pharmaceutically acceptable salt thereof.
[0076] Ether lipid (ETL) and ether phospholipid (ETPL) compounds of the present disclosure have an alkyl chain in which the n-alkyl chain is a C13-C22 n-alkyl chain or a C13- C24 n-alkyl chain. In some embodiments, the n-alkyl chain is a C18-C22 n-alkyl chain or a C21- C24 n-alkyl chain. In some embodiments, the n-alkyl chain is a C16-C20 n-alkyl chain. In some embodiments, the n-alkyl chain is a C21-C24 n-alkyl chain. In some preferred embodiments, the n-alkyl chain is a C22 n-alkyl chain. Structures of exemplary ETPL and ETL compounds of the present disclosure are shown in Table II and Table III below, respectively. The structures shown in Table II and Table III can alternatively be protonated or deprotonated forms of the structures shown in Table II and Table III, that is, where protonated indicates a proton on any or all phosphate oxygens depicted as O- below, and where deprotonated indicates removal of a proton from any or all phosphate OH group; and / or can be a salt of the structures shown in Table II and Table III, such as a pharmaceutically acceptable salt thereof.
[0077] Syntheses of the ether lipid and ether phospholipid compounds disclosed herein are presented in Synthetic Schemes 1 to 8 and Synthetic Examples S-1 to S-8 of PCT / US2023 / 077220 of Corner Therapeutics, Inc., filed October 18, 2023, and are hereby incorporated by reference. Table II. Exemplary Ether Phospholipid (ETPL) Compoundssf-5700344Docket No.: 16553-20009.40sf-5700344Docket No.: 16553-20009.40In column 1, “No.” refers to compound number.sf-5700344Docket No.: 16553-20009.40 Table III. Exemplary Ether Lipid (ETL) Compoundssf-5700344Docket No.: 16553-20009.40C. Phospholipid Analog (PLA) Compounds
[0078] The phospholipid analogs for use in the compositions and methods disclosed herein comprise at least a phosphate group and an n-alkyl “tail.” Exemplary phospholipid analogs include edelfosine (EDEL), miltefosine (MILT), and perifosine (PERIF). Structures of exemplary PLA compounds of the present disclosure are shown in Table IV. In some embodiments, the n-alkyl tail is a C16-C18 n-alkyl tail. In some embodiments, the n-alkyl tail is a C18 n-alkyl tail. In other embodiments, the n-alkyl tail is a C16 n-alkyl tail.
[0079] The phospholipid analogs can be protonated or can be deprotonated, that is, where protonated indicates addition of a proton to any or all free phosphate O- groups, and where deprotonated indicates removal of a proton from any or all free phosphate OH groups. The phospholipid analogs can be in salt form, such as pharmaceutically acceptable salts.sf-5700344Docket No.: 16553-20009.40 Table IV. Exemplary Phospholipid Analog CompoundsIII. Pathogen Recognition Receptor Agonists
[0080] Compositions and methods of the present disclosure may further comprise a pathogen recognition receptor (PRR) agonist. In some embodiments, the PRR agonist comprises an agonist of a toll-like receptor (TLR), a NOD-like receptor (NLR), a RIG-I-like receptor (RLR), or a C-type lectin receptor (CLR). In other embodiments, the PRR agonist comprises a cytosolic DNA sensor (CDS) or a stimulator of IFN genes (STING). In some embodiments, the PRR agonist comprises a TLR7 / 8 agonist. A. TLR7 / 8 Agonists
[0081] The term “TLR7 / 8 agonist” as used herein refers to an agonist of TLR7 and / or TLR8. In one aspect, the TLR7 / 8 agonist is a TLR7 agonist. In another aspect, the TLR7 / 8 agonist is a TLR8 agonist. In a further aspect, the TLR7 / 8 agonist is an agonist of both TLR7 and TLR8. TLR7 / 8 agonists of the present disclosure are suitable for hyperactivating human dendritic cells in the presence of LPC.sf-5700344Docket No.: 16553-20009.40
[0082] In some aspects, the TLR7 / 8 agonist is a small molecule. In some embodiments, the TLR7 / 8 agonist is a small molecule with a molecule weight of 900 daltons or less, or a salt thereof. That is, the small molecule TLR7 / 8 agonist is not a large molecule like a recombinant protein or a synthetic oligonucleotide, which is regulatable by the U.S. FDA’s Center for Biologics Evaluation and Research. Rather the small molecule TLR7 / 8 agonist is regulatable by the FDA’s Center for Drug Evaluation and Research. In some embodiments, the small molecule has a molecule weight of from about 90 to about 900 daltons. In some embodiments, the TLR7 / 8 agonist comprises an imidazoquinoline compound. In some preferred embodiments, the TLR7 / 8 agonist comprises resiquimod (R848). B. Other PRR Agonists
[0083] In some aspects, the pathogen recognition receptor (PRR) agonist comprises a toll-like receptor (TLR) agonist. In the embodiments described in the previous section, the TLR agonist comprises a TLR7 / 8 agonist. In other embodiments, the TLR agonist does not comprise a TLR7 / 8 agonist. In some embodiments, the TLR agonist comprises an agonist of one or more of TLR2, TLR3, TLR4, TLR5, TLR9 and TLR13. In some embodiments, the PRR agonist is a TLR2 / 6 agonist, such as Pam2CSK4. In other embodiments, the TLR agonist is a TLR4 agonist such as monophosphoryl lipid A (MPLA). However, in preferred embodiments, the TLR agonist is not an agonist of TLR2, TLR4 and / or TLR9. For instance, in preferred embodiments, the TLR9 agonist is not a TLR4 ligand such as LPS (endotoxin).
[0084] In other aspects, the PRR agonist comprises a NOD-like receptor (NLR) agonist. In further aspects, the PRR agonist comprises a RIG-I-like receptor (RLR) agonist. In additional aspects, the PRR agonist comprises a C-type lectin receptor (CLR) agonist. In still further aspects, the PRR agonist comprises a CDS agonist or a STING agonist. IV. Pharmaceutical Formulations
[0085] Some compositions of the present disclosure are pharmaceutical formulations comprising a pharmaceutically acceptable excipient, a tumor cell lysate and an isolated bystander antigen (tumor and bystander antigens), and optionally a PRR agonist (e.g., TLR7 / 8 agonist) and / or a hyperactivating lipid (e.g., glycerolipid or phospholipid analog). Pharmaceutical formulations of the present disclosure may be in the form of a solution or a suspension.sf-5700344Docket No.: 16553-20009.40 Alternatively, the pharmaceutical formulations may be a dehydrated solid (e.g., freeze dried or spray dried solid). The pharmaceutical formulations of the present disclosure are preferably sterile, and preferably essentially endotoxin-free. The term “pharmaceutical formulations” is used interchangeably herein with the terms “medicinal product” and “medicament”. In some embodiments, the pharmaceutical formation comprises specific ratios of the various components based on the intended purpose of the formulation. In some embodiments, the pharmaceutical formulations comprise a non-ionic surfactant. In some embodiments, the non-ionic surfactant comprises an ethylene oxide-propylene oxide copolymer, such as Poloxamer-407 (CAS Registry No.977057-91-2). A. Excipients
[0086] Pharmaceutically acceptable excipients of the present disclosure include for instance, solvents, buffering agents, tonicity adjusting agents, bulking agents, and preservatives (See, e.g., Pramanick et al., Pharma Times, 45:65-77, 2013). In some embodiments, the pharmaceutical formulations may comprise an excipient that functions as one or more of a solvent, a buffering agent, a tonicity adjusting agent, and a bulking agent (e.g., sodium chloride in saline may serve as both an aqueous vehicle and a tonicity adjusting agent). Pharmaceutically acceptable excipients of the present disclosure also include detergents, wetting agents, emulsifiers, foaming agents, and dispersants, as well as surfactants.
[0087] Many of the lipids disclosed herein are sparingly soluble in water. Surfactants can be used to solubilize the lipids in aqueous formulations. A wide variety of surfactants are available, which can be classified as anionic surfactants, non-ionic surfactants, cationic surfactants, and zwitterionic surfactants.
[0088] Some examples of non-ionic surfactants include poloxamers, which are triblock copolymers of ethylene oxide and propylene oxide of the general formula: HO-[CH2CH2-O-]a-[CH2CH(CH3)-O-]b-[CH2-CH2-O-]a-H. Some poloxamers are sold under the trade name Pluronic® (PLURONIC is a registered trademark of BASF SE, Ludwigshafen, Germany). Examples of poloxamers are Poloxamer 407 (KP407; a = 101, b = 56); Poloxamer 188 (KP188; a = 80, b = 27); Pluronic® P84 (P-84; a = 19, b = 39); and Pluronic® P123 (P-123; a = 20, b =70) (the foregoing values for a and b may be subject to slight variation).sf-5700344Docket No.: 16553-20009.40
[0089] Other non-ionic surfactants include the Cremophor® series (CREMAPHOR is a registered trademark of BASF SE, Ludwigshafen, Germany). Cremophor® surfactants include Cremophor® EL (K EL), a mixture of polyoxyethylated triglycerides produced by reacting castor oil with ethylene oxide in a molar ratio of approximately 1:35, and Cremophor® RH40 (also known as Kolliphor® RH40; KOLLIPHOR is a registered trademark of BASF SE), obtained by reacting 40 moles of ethylene oxide with 1 mole of hydrogenated castor oil.
[0090] In some embodiments, the pharmaceutical formulations comprise an aqueous vehicle as a solvent. Suitable vehicles include for instance sterile water, saline solution, phosphate buffered saline, and Ringer's solution. In some embodiments, the composition is isotonic.
[0091] The pharmaceutical formulations may comprise a buffering agent. Buffering agents control pH to inhibit degradation of the active agent during processing, storage and optionally reconstitution. Suitable buffers include for instance salts comprising acetate, citrate, phosphate or sulfate. Other suitable buffers include for instance amino acids such as arginine, glycine, histidine, and lysine. The buffering agent may further comprise hydrochloric acid or sodium hydroxide. In some embodiments, the buffering agent maintains the pH of the composition within a range of 6 to 9. In some embodiments, the pH is greater than (lower limit) 6, 7 or 8. In some embodiments, the pH is less than (upper limit) 9, 8, or 7. That is, the pH is in the range of from about 6 to 9 in which the lower limit is less than the upper limit.
[0092] The pharmaceutical compositions may comprise a tonicity adjusting agent. Suitable tonicity adjusting agents include for instance dextrose, glycerol, sodium chloride, glycerin and mannitol.
[0093] The pharmaceutical formulations may comprise a bulking agent. Bulking agents are particularly useful when the pharmaceutical composition is to be lyophilized before administration. In some embodiments, the bulking agent is a protectant that aids in the stabilization and prevention of degradation of the active agents during freeze or spray drying and / or during storage. Suitable bulking agents are sugars (mono-, di- and polysaccharides) such as sucrose, lactose, trehalose, mannitol, sorbital, glucose and raffinose.sf-5700344Docket No.: 16553-20009.40
[0094] The pharmaceutical formulations may comprise a preservative. Suitable preservatives include for instance antioxidants and antimicrobial agents. However, in preferred embodiments, the pharmaceutical formulation is prepared under sterile conditions and is in a single use container, and thus does not necessitate inclusion of a preservative.
[0095] The pharmaceutical formulations of the present disclosure are suitable for parenteral administration. That is the pharmaceutical formulations of the present disclosure are not intended for enteral administration (e.g., not by orally, gastrically, or rectally). B. Adjuvants
[0096] Pharmaceutically acceptable adjuvants of the present disclosure include for instance, an aluminum salt adjuvant, a squalene-in-water emulsion, a saponin, or combinations thereof. In some embodiments, the adjuvant is an aluminum salt adjuvant selected from the group consisting of amorphous aluminum hydroxyphosphate sulfate, aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate, and combinations thereof. In other embodiments, the adjuvant is a squalene-in-water emulsion such as MF59 or AS03. In other embodiments, the adjuvant is a saponin, such as Quil A or QS-21, as in AS01 or AS02. V. Methods for Production
[0097] The present disclosure relates, in some aspects, to methods for preparing immunogenic compositions comprising a tumor cell lysate and an isolated bystander antigen (tumor and bystander antigens), and optionally a pathogen recognition receptor (PRR) agonist (e.g., TLR7 / 8 agonist) and / or a hyperactivating lipid (e.g., glycerolipid or phospholipid analog). The immunogenic compositions are suitable for stimulating immune responses against the antigens in a mammalian subject in need thereof (e.g., cancer patient). In some aspects, the present disclosure provides methods for preparing an immunogenic composition, comprising: contacting a tumor cell lysate, prepared from a tumor of a mammalian subject, with an isolated bystander antigen to obtain the immunogenic composition, wherein the bystander antigen comprises a polypeptide that is heterologous to the mammalian subject. In some embodiments, the contacting step further comprises contacting the tumor cell lysate with an isolated glycerolipid or phospholipid analog, and / or a PRR agonist.sf-5700344Docket No.: 16553-20009.40
[0098] In some embodiments, the present disclosure provides methods for production of an immunogenic composition, comprising: a) lysing cells from a tumor to obtain a tumor cell lysate; and b) contacting the tumor cell lysate with an isolated bystander antigen, and one or both of a PRR agonist (e.g., TLR7 / 8 agonist) and a hyperactivating lipid (e.g., glycerolipid or phospholipid analog) to obtain the immunogenic composition. In further embodiments, the present disclosure provides methods of preparing an immunogenic composition, the method comprising: a) obtaining a tumor cell suspension from a tumor of a mammalian subject; b) lysing cells from the tumor cell suspension to obtain a tumor cell lysate; and c) contacting the tumor cell lysate with an isolated bystander antigen, an isolated glycerolipid or phospholipid analog, and a PRR agonist to obtain the immunogenic composition, wherein the bystander antigen comprises a polypeptide that is heterologous to the mammalian subject.
[0099] In some embodiments of the methods described above, the cells are lysed by a physical disruption-based cell lysis method, such as, but not limited to, mechanical lysis, liquid homogenization, sonication, freeze-thaw, or manual grinding. In some preferred embodiments, the cells are lysed by one or more freeze-thaw cycles. In some embodiments, the tumor cell lysate is a whole tumor lysate (e.g., cells of the tumor were not subject to positive or negative selection prior to preparation of the lysate). In some embodiments, cells from the tumor are not contacted with the bystander antigen and / or are not cultured in vitro prior to preparation of the tumor cell lysate. VI. Methods of Use
[0100] In some aspects, the present disclosure relates to methods of use of any one of the immunogenic compositions or formulations described herein, which comprise a tumor cell lysate and an isolated bystander antigen (tumor and bystander antigens), and optionally a PRR agonist (e.g., TLR7 / 8 agonist) and / or a hyperactivating lipid (e.g., glycerolipid or phospholipid analog). The immunogenic compositions are suitable for stimulating an immune response against the tumor and bystander antigens. In some embodiments, the methods of use comprise methods of treating cancer. In some embodiments, the methods of use comprise methods of inhibiting abnormal cell proliferation. The methods comprise administering an effective amount of asf-5700344Docket No.: 16553-20009.40 formulation or a composition described herein to an individual in need thereof to achieve a specific outcome. The individual is a mammalian subject, such as a human patient. In other embodiments, the individual is a non-human patient. In some embodiments, the individual is a canine patient. That is in some embodiments, the methods of use involve clinical uses, while in other embodiments the methods of use involve pre-clinical and / or veterinary uses. For preclinical uses, the mammalian subject may be a non-human primate (e.g., monkey or ape) or a rodent (e.g., mouse or rat). For veterinary uses the mammalian subject may be a farm animal (e.g., cow), a sport animal (e.g., horse), or a pet (e.g., companion animal such as a dog or cat). A. Stimulation of an Immune Response
[0101] In brief, the present disclosure provides methods of stimulating an immune response in a mammalian subject, comprising administering to the subject an immunogenic composition or formulation described herein in an amount sufficient to stimulate an immune response against the tumor cell lysate and the bystander antigen (tumor and bystander antigens) in the subject. “Stimulating” an immune response (used interchangeably with “eliciting” an immune response), means increasing the immune response, which can arise from eliciting a de novo immune response (e.g., as a consequence of an initial vaccination regimen) or enhancing an existing immune response (e.g., as a consequence of a booster vaccination regimen). In some embodiments, stimulating an immune response comprises one or more of the group consisting of: stimulating cytokine production; stimulating B lymphocyte proliferation; stimulating interferon pathway-associated gene expression; stimulating chemoattractant-associated gene expression; and stimulating dendritic cell DC maturation. Methods for measuring stimulation of an immune response are known in the art. In some preferred embodiments, the immune response may comprise one or more of an antigen-specific antibody response, an antigen-specific cytotoxic T lymphocyte (CTL) response, and an antigen-specific helper T (Th) cell response. “Inducing” an antigen-specific antibody response means increasing titer of the antigen-specific antibodies above a threshold level such as a pre-administration baseline titer or a seroprotective level. “Inducing” an antigen-specific CTL response means increasing frequency of antigen- specific CTL found in peripheral blood above a pre-administration baseline frequency. “Inducing” an antigen-specific Th cell response means increasing frequency of antigen-specific Th cells found in peripheral blood above a pre-administration baseline frequency. In preferredsf-5700344Docket No.: 16553-20009.40 embodiments, the tumor cell lysate-reactive immune response is also reactive with tumor cells that have not been lysed.
[0102] Analysis (both qualitative and quantitative) of the immune response can be by any method known in the art, including, but not limited to, measuring antigen-specific antibody production (including measuring specific antibody subclasses), activation of specific populations of lymphocytes such as B cells and helper T cells, production of cytokines such as IFN-alpha, IFN-gamma, IL-6, IL-12 and / or release of histamine. Methods for measuring antigen-specific antibody responses include enzyme-linked immunosorbent assay (ELISA). Activation of specific populations of lymphocytes can be measured by proliferation assays, and with fluorescence-activated cell sorting (FACS). Production of cytokines can also be measured by ELISA. In some embodiments, methods of stimulating an immune response comprise stimulation of interleukin-1beta (IL-^ȕ^^VHFUHWLRQ^^LQWHUIHURQ-gamma (IFN-Ȗ^^VHFUHWLRQ^^DQG^RU^ tumor necrosis factor-alpha (TNF-Į^^secretion by monocyte-derived dendritic cells or peripheral blood mononuclear cells. In some embodiments, methods of stimulating an immune response comprise stimulation of secretion of one or more of IFN-Ȗ^^, / -17a, IL-17f, and IL-22 by memory CD4+ T cells. In some embodiments, methods of stimulating an immune response comprise increasing Th1 differentiation of naïve CD4+ T cells. In some preferred embodiments, at least 50%, 55%, 60%, 65%, 70% or 75% of the cells contacted with a composition of the present disclosure remain viable at 40-56 hours (or about 48 hours) post-contact.
[0103] The methods and medicaments of the present disclosure are suitable for stimulating an anti-tumor immune response. When the bystander antigen of the immunogenic composition is a microbial antigen, the methods are also suitable for stimulating an anti-microbe immune response. In some embodiments, the anti-microbe response is an anti-bacterial immune response. In some embodiments, the anti-microbe response is an anti-fungal immune response. In some embodiments, the anti-microbe response is, an anti-viral immune response. In some embodiments, the anti-microbe response is an anti-protozoan immune response. B. Treating or Preventing Disease
[0104] The present disclosure further provides methods of treating or preventing a disease in an individual, comprising administering to the individual a composition or formulation described herein in an amount sufficient to treat or prevent a disease in the individual. In somesf-5700344Docket No.: 16553-20009.40 embodiments, the disease is cancer. In some embodiments, the disease is abnormal cell proliferation. In other embodiments, the disease is an infectious disease.
[0105] In some embodiments, the methods involve treating cancer in an individual or otherwise treating a mammalian subject with cancer. In some embodiments, the methods comprise: a) preparing an immunogenic composition comprising a tumor cell lysate, and a bystander antigen (tumor and bystander antigens), and optionally a PRR agonist (e.g., TLR7 / 8 agonist) and / or a hyperactivating lipid (e.g., glycerolipid or phospholipid analog), wherein the tumor cell lysate is or has been prepared from a sample of a tumor obtained from the subject with cancer; and b) administering to the subject an effective amount of the immunogenic composition. In some embodiments, the cancer is a hematologic cancer, such as a lymphoma, a leukemia, or a myeloma. In other embodiments, the cancer is a non-hematologic cancer, such as a sarcoma, a carcinoma, or a melanoma. In some embodiments, the cancer is malignant.
[0106] In some embodiments, the methods involve inhibiting abnormal cell proliferation in an individual. “Abnormal cell proliferation” refers to proliferation of a benign tumor or a malignant tumor. The malignant tumor may be a metastatic tumor.
[0107] In some embodiments when the bystander antigen is an antigen of a microbe, the methods involve treating or preventing an infectious disease in an individual in which the disease is caused by infection with the microbe. In some embodiments, the infectious disease is caused by a viral infection. In other embodiments, the infectious disease is caused by a bacterial infection. In further embodiments, the infectious disease is caused by a fungal infection. In still further embodiments, the infectious disease is caused by a protozoal infection. Of particular importance are infectious diseases caused by zoonotic pathogens that infect humans as well as other animals such as mammals or birds. In some embodiments, the zoonotic pathogen is transmitted to humans via an intermediate species (vector).sf-5700344Docket No.: 16553-20009.40 VII. Enumerated Embodiments 1. An immunogenic composition comprising a tumor cell lysate and an isolated bystander antigen, wherein the tumor cell lysate is prepared from a tumor of a mammalian subject, the isolated bystander antigen comprises a polypeptide that is heterologous to the mammalian subject. 2. The composition of embodiment 1, wherein the composition further comprises a pathogen recognition receptor (PRR) agonist. 3. The composition of embodiment 1, wherein the composition further comprises a lipid, wherein the lipid comprises a glycerolipid or a phospholipid analog. 4. The composition of embodiment 1, wherein the immunogenic composition further comprises a lipid and a PRR agonist, wherein the lipid comprises a glycerolipid or a phospholipid analog. 5. The composition of any one of embodiments 1-4, wherein the bystander antigen comprises a mammalian antigen, an avian antigen, a reptilian antigen, or an amphibian antigen. 6. The composition of any one of embodiments 1-4, wherein the bystander antigen comprises a mammalian antigen, and wherein the mammalian antigen is of different taxonomic genus, family, or order than the mammalian subject. 7. The composition of any one of embodiments 1-4, wherein the bystander antigen comprises a microbial antigen. 8. The composition of embodiment 7, wherein the microbial antigen comprises one or more of a viral antigen, a bacterial antigen, a protozoan antigen, and a fungal antigen. 9. The composition of embodiment 7, wherein the microbial antigen comprises a viral antigen. 10. The composition of embodiment 9, wherein the viral antigen comprises an inactivated, whole virus. 11. The composition of any one of embodiments 1-9, wherein the bystander antigen comprises a synthetic or recombinant polypeptide.sf-5700344Docket No.: 16553-20009.40 12. The composition of any one of embodiments 1-9, wherein the bystander antigen comprises a native polypeptide. 13. The composition of any one of embodiments 1-12, wherein the polypeptide is from about 20 to about 2000 amino acids in length, optionally from about 30 to about 1700 amino acids in length, optionally from about 40 to about 1600 amino acids in length, optionally from about 50 to about 1500 amino acids length, optionally from about 60 to about 1400 amino acids length, optionally from about 70 to about 1300 amino acids length, optionally from about 80 to about 1200 amino acids length, optionally from about 90 to about 1100 amino acids length, optionally from about 100 to about 1000 amino acids length. 14. The composition of any one of embodiments 3-13, wherein the lipid comprises a glycerolipid, optionally wherein the glycerolipid comprises a C13-C24 acyl chain or a C13-C24 alkyl chain, optionally wherein the glycerolipid comprises a C19-C22 acyl chain or a C19-C22 alkyl chain. 15. The composition of embodiment 14, wherein the glycerolipid is an isolated ether lipid (ETL). 16. The composition of embodiment 15, wherein the ETL is an isolated ether phospholipid (ETPL). 17. The composition of embodiment 16, wherein the ETPL comprises 1-docosyl-sn- glycerol-3-phosphate (DGP), or a pharmaceutically acceptable salt thereof. 18. The composition of embodiment 16, wherein the ETPL comprises 1-docosyl-sn- glycerol-3-phosphocholine (DGPC), or a pharmaceutically acceptable salt thereof. 19. The composition of any one of embodiments 3-13, wherein the lipid comprises a phospholipid analog, optionally wherein the phospholipid analog comprises a C13-C24 acyl chain or a C13-C24 alkyl chain, optionally wherein the phospholipid analog comprises a C16- C18 acyl chain or a C16-C18 alkyl chain. 20. The composition of embodiment 19, wherein the phospholipid analog is selected from the group consisting of edelfosine, miltefosine and perifosine.sf-5700344Docket No.: 16553-20009.40 21. The composition of embodiment 14, wherein the glycerolipid comprises an isolated lysophosphatidylcholine (LPC) having a single acyl chain. 22. The composition of embodiment 21, wherein the acyl chain is a C22 acyl chain. 23. The composition of embodiment 22, wherein the acyl chain is fully saturated. 24. The composition of embodiment 23, wherein the isolated LPC comprises 1- behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)]. 25. The composition of embodiment 14, wherein the glycerolipid comprises oxPAPC or an isolated species of oxPAPC. 26. The composition of embodiment 25, wherein the species of oxPAPC comprises one or more of PGPC, HOdiA-PC, KOdiA-PC, HOOA-PC, and KOOA-PC. 27. The composition of embodiment 25, wherein the species of oxPAPC comprises PGPC. 28. The composition of any one of embodiments 1-27, wherein the composition does not comprise LPS or MPLA. 29. The composition of any one of embodiments 1-28, wherein the PRR agonist is an agonist of a toll-like receptor (TLR), an agonist of a NOD-like receptor (NLR), an agonist of a RIG-I-like receptor (RLR), or an agonist of a C-type lectin receptor (CLR). 30. The composition of embodiment 29, wherein PRR agonist comprises a TLR7 / 8 agonist. 31. The composition of embodiment 30, wherein the TLR7 / 8 agonist is a small molecule with a molecule weight of 900 daltons or less. 32. The composition of embodiment 31, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound. 33. The composition of embodiment 32, wherein the TLR7 / 8 agonist comprises resiquimod (R848). 34. The composition of embodiment 32 or embodiment 33, wherein the TLR7 / 8 agonist does not inhibit NLR family pyrin domain containing 3 (NLRP3).sf-5700344Docket No.: 16553-20009.40 35. The composition of embodiment 29, wherein the PRR agonist is an agonist of a cytosolic DNA sensor (CDS) or a stimulator of IFN genes (STING). 36. The composition of embodiment 29, wherein the PRR agonist comprises one or more of R848, TL8-506, LPS, Pam2CSK4, and ODN 2336. 37. The composition of any one of embodiments 4-13, wherein the immunogenic composition comprises a glycerolipid comprising 1-behenoyl-2-hydroxy-sn-glycero-3- phosphocholine [LPC(22:0)], and the TLR7 / 8 agonist comprises resiquimod (R848). 38. The composition of any one of embodiments 4-13, wherein the immunogenic composition comprises a glycerolipid comprising 1-docosyl-sn-glycerol-3-phosphate (DGP), or a pharmaceutically acceptable salt thereof, and the TLR7 / 8 agonist comprises resiquimod (R848). 39. The composition of any one of embodiments 4-13, wherein the immunogenic composition comprises a glycerolipid comprising 1-docosyl-sn-glycerol-3-phosphocholine (DGPC), or a pharmaceutically acceptable salt thereof, and the TLR7 / 8 agonist comprises resiquimod (R848). 40. The composition of any one of embodiments 4-13, wherein the immunogenic composition comprises a phospholipid analog comprising edelfosine, miltefosine or perifosine, and the TLR7 / 8 agonist comprises resiquimod (R848). 41. The composition of any one of embodiments 1-40, wherein the immunogenic composition further comprises a surfactant. 42. The composition of embodiment 41, wherein the surfactant comprises a non-ionic surfactant. 43. The composition of embodiment 42, wherein the non-ionic surfactant comprises an ethylene oxide-propylene oxide copolymer. 44. The composition of embodiment 42, wherein the non-ionic surfactant comprises one or more of Poloxamer 407, Poloxamer 188, and P123. 45. The composition of embodiment 42, wherein the non-ionic surfactant comprises Poloxamer 407.sf-5700344Docket No.: 16553-20009.40 46. The composition of any one of embodiments 42-45, wherein the non-ionic surfactant is present in an amount of about 0.5% to about 50% (w / w), optionally in an amount of about 2.5% to about 25% (w / w), optionally in an amount of about 5% to about 20% (w / w), optionally in an amount of about 10% to about 15% (w / w). 47. The composition of any one of embodiments 1-46, wherein the immunogenic composition further comprises a pharmaceutically acceptable excipient. 48. The composition of any one of embodiments 1-47, wherein the immunogenic composition further comprises an adjuvant, optionally wherein the adjuvant comprises an aluminum salt adjuvant, a squalene-in-water emulsion, a saponin, or combinations thereof. 49. The composition of any one of embodiments 1-48, wherein the tumor cell lysate is a whole tumor lysate. 50. The composition of any one of embodiments 1-49, wherein cells from the tumor are not contacted with the bystander antigen or cultured in vitro prior to preparation of the tumor cell lysate. 51. The composition of any one of embodiments 1-50, wherein the tumor cell lysate was prepared from a sample of the tumor obtained through biopsy of the tumor or surgical excision of the tumor. 52. The composition of embodiment 51, wherein the sample was subjected to mechanical dissociation and enzymatic digestion to produce a tumor cell suspension prior to preparation of the tumor cell lysate. 53. The composition of embodiment 52, wherein the tumor cells were lysed by one or more freeze-thaw cycles. 54. The composition of any one of embodiments 1-53, wherein the tumor is a solid tumor, optionally wherein the solid tumor is a melanoma, a carcinoma, or a sarcoma. 55. A method of stimulating an anti-tumor immune response, the method comprising administering an effective amount of the immunogenic composition of any one of embodiments 1-54 to the mammalian subject to stimulate an immune response against the tumor cell lysate andsf-5700344Docket No.: 16553-20009.40 the bystander antigen, optionally wherein the immune response is reactive with cells of the subject’s tumor. 56. A method of treating cancer, the method comprising administering an effective amount of the immunogenic composition of any one of embodiments 1-54 to the mammalian subject to treat the cancer. 57. A method of inhibiting abnormal cell proliferation, comprising administering an effective amount of the immunogenic composition of any one of embodiments 1-54 to the mammalian subject to inhibit abnormal cell proliferation. 58. A method of treating or preventing an infectious disease, comprising administering an effective amount of the immunogenic composition of any one of embodiments 7-54 to the mammalian subject to treat or prevent the infectious disease, wherein the microbial antigen is of the causative agent of the infectious disease. 59. Use of the immunogenic composition of any one of embodiments 1-54 for inducing an immune response against the tumor cell lysate and the bystander antigen in the mammalian subject. 60. Use of the immunogenic composition of any one of embodiments 1-54 for treating cancer in the mammalian subject. 61. Use of the immunogenic composition of any one of embodiments 1-54 for inhibiting abnormal cell proliferation in the mammalian subject. 62. Use of the immunogenic composition of any one of embodiments 7-54 for treating or preventing an infectious disease in the mammalian subject, wherein the microbial antigen is of the causative agent of the infectious disease. 63. The composition, method or use of any one of embodiments 1-62, wherein the mammalian subject is a human subject. 64. A method of preparing an immunogenic composition, the method comprising: contacting a tumor cell lysate, prepared from a tumor of a mammalian subject, with an isolated bystander antigen to obtain the immunogenic composition, wherein the bystander antigen comprises a polypeptide that is heterologous to the mammalian subject.sf-5700344Docket No.: 16553-20009.40 65. The method of embodiment 64, wherein the contacting step further comprises contacting the tumor cell lysate with an isolated glycerolipid or phospholipid analog, and / or a pathogen recognition receptor (PRR) agonist. 66. A method of preparing an immunogenic composition, the method comprising: a) obtaining a tumor cell suspension from a tumor of a mammalian subject; b) lysing cells from the tumor cell suspension to obtain a tumor cell lysate; and c) contacting the tumor cell lysate with an isolated bystander antigen, an isolated glycerolipid or phospholipid analog, and a pathogen recognition receptor (PRR) agonist to obtain the immunogenic composition, wherein the bystander antigen comprises a polypeptide that is heterologous to the mammalian subject. 67. The method of embodiment 66, wherein the cells are lysed in step b) by one or more freeze-thaw cycles. 68. The method of embodiment 66 or embodiment 67, wherein the tumor cell suspension was prepared from a sample of the tumor obtained through biopsy of the tumor or surgical excision of the tumor. 69. The method of embodiment 68, wherein the sample was subjected to mechanical dissociation and enzymatic digestion to produce the tumor cell suspension. 70. The method of any one of embodiments 64-69, wherein the tumor is a solid tumor, optionally wherein the solid tumor is a melanoma, a carcinoma, or a sarcoma. 71. The method of any one of embodiments 64-69, wherein the tumor is a lymphoma. 72. The method of any one of embodiments 64-71, wherein the bystander antigen comprises a mammalian antigen, an avian antigen, a reptilian antigen, or an amphibian antigen. 73. The method of embodiment 72, wherein the bystander antigen comprises a mammalian antigen, and wherein the mammalian antigen is of different taxonomic genus, family, or order than the mammalian subject. 74. The method of any one of embodiments 64-71, wherein the bystander antigen comprises a microbial antigen.sf-5700344Docket No.: 16553-20009.40 75. The method of embodiment 74, wherein the microbial antigen comprises one or more of a viral antigen, a bacterial antigen, a protozoan antigen, and a fungal antigen. 76. The method of embodiment 74, wherein the microbial antigen comprises a viral antigen. 77. The method of embodiment 76, wherein the viral antigen comprises an inactivated, whole virus. 78. The method of any one of embodiments 64-77, wherein the bystander antigen comprises a synthetic or recombinant polypeptide. 79. The method of any one of embodiments 64-77, wherein the bystander antigen comprises a native polypeptide. 80. The method of any one of embodiments 64-79, wherein the polypeptide is from about 8 to about 8000 amino acids in length, optionally from about 20 to about 2000 amino acids in length, optionally from about 30 to about 1700 amino acids in length, optionally from about 40 to about 1600 amino acids in length, optionally from about 50 to about 1500 amino acids length, optionally from about 60 to about 1400 amino acids length, optionally from about 70 to about 1300 amino acids length, optionally from about 80 to about 1200 amino acids length, optionally from about 90 to about 1100 amino acids length, optionally from about 100 to about 1000 amino acids length. 81. The method of any one of embodiments 65-80, wherein the contacting step comprises contacting the tumor cell lysate with an isolated bystander antigen, an isolated glycerolipid, and a pathogen recognition receptor (PRR) agonist to obtain the immunogenic composition. 82. The method of embodiment 81, wherein the isolated glycerolipid comprises an isolated lysophosphatidylcholine (LPC) having a single C19-C22 acyl chain. 83. The method of embodiment 82, wherein the isolated LPC comprises 1-behenoyl- 2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)]. 84. The method of embodiment 81, wherein the isolated glycerolipid comprises an isolated ether phospholipid (ETPL).sf-5700344Docket No.: 16553-20009.40 85. The method of embodiment 84, wherein the ETPL comprises 1-docosyl-sn- glycerol-3-phosphate (DGP), or a pharmaceutically acceptable salt thereof. 86. The method of embodiment 84, wherein the ETPL comprises 1-docosyl-sn- glycerol-3-phosphocholine (DGPC), or a pharmaceutically acceptable salt thereof. 87. The method of any one of embodiments 65-80, wherein the contacting step comprises contacting the tumor cell lysate with an isolated bystander antigen, an isolated phospholipid analog, and a pathogen recognition receptor (PRR) agonist to obtain the immunogenic composition. 88. The method of embodiment 87, wherein the phospholipid analog is selected from the group consisting of edelfosine, miltefosine and perifosine. 89. The method of any one of embodiments 64-88, wherein the PRR agonist is an agonist of a toll-like receptor (TLR), an agonist of a NOD-like receptor (NLR), an agonist of a RIG-I-like receptor (RLR), or an agonist of a C-type lectin receptor (CLR). 90. The method of embodiment any one of embodiments 64-88, wherein PRR agonist comprises a TLR7 / 8 agonist. 91. The method of embodiment 90, wherein the TLR7 / 8 agonist is a small molecule with a molecule weight of 900 daltons or less. 92. The method of embodiment 91, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound. 93. The method of embodiment 92, wherein the TLR7 / 8 agonist comprises resiquimod (R848). 94. The method of any one of embodiments 64-93, wherein the tumor cell lysate is a whole tumor lysate. 95. The method of any one of embodiments 64-94, wherein cells from the tumor are not contacted with the bystander antigen or cultured in vitro prior to preparation of the tumor cell lysate in step b). 96. An immunogenic composition prepared by the method of any one of embodiments 64-95.sf-5700344Docket No.: 16553-20009.40 97. A method of eliciting an anti-cancer immune response, the method comprising: administering to a mammalian subject with cancer an effective amount of the immunogenic composition of embodiment 95. 98. The method of embodiment 97, wherein the anti-cancer immune response comprises a cellular immune response. 99. The method of embodiment 98, wherein the cellular immune response comprises tumor cell lysate-induced interferon-gamma secretion by CD8+ and / or CD4+ T lymphocytes. 100. The method of any one of clams 97-99, further comprising administering to the subject an effective amount of an additional therapeutic agent. 101. The method of embodiment 100, wherein the additional therapeutic agent comprises one or more of the group consisting of an immune checkpoint inhibitor, an antineoplastic agent, and radiation therapy. 102. Invention, in any form of its embodiments or in any claim category applicable for claiming, e.g., product or process or use encompassed by the subject-matter initially described, disclosed or illustrated in the patent application.sf-5700344Docket No.: 16553-20009.40 EXAMPLES
[0108] Abbreviations: BM (bone marrow); BMDC (bone marrow-derived dendritic cell); BSA (bovine serum albumin); DAMP (danger-associated molecular pattern); DC (dendritic cell); DGP (1-docosyl-sn-glycerol-3-phosphate); DGPC (1-docosyl-sn-glycerol-3- phosphocholine); HA (hemagglutinin); ,)1Ȗ^^LQWHUIHURQ-gamma); IL-1b / IL1-beta / IL-^ȕ^ (Interleukin-1beta); KP407 (poloxamer 407); LPC or lysoPC or LysoPC (lysophosphatidylcholine); LysoPC(22:0) (1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine); LPS (lipopolysaccharide); moDC (monocyte-derived dendritic cell); OVA (ovalbumin); PAMP (pathogen-associated molecular pattern); R848 (resiquimod); 71)Į^^WXPRU^QHFURVLV^IDFWRU- alpha); TLR (toll-like receptor); and WTL (whole tumor lysate).
[0109] Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore, the following examples should not be construed as limiting the scope of the present disclosure, which is delineated by the appended claims. Example 1: Increasing Immunogenicity of Whole Tumor Lysates by Inclusion of a Bystander Antigen
[0110] This example describes the use of a bystander antigen to improve the immune response to tumor antigens. Material and Methods
[0111] Murine bone marrow-derived FLT3L-DCs generation. Leg femur and tibia were removed from mice, cut with scissors, and flushed into sterile tubes. Bone marrow suspension was treated with ACK for 1 minute, then passed through a 40μm cell strainer. Cells were counted and resuspended in media consisting of complete IMDM containing 10% FBS, penicillin and streptomycin, and supplements of L-glutamine and sodium pyruvate (I10). Cellswere then plated at 8x106 bone marrow cells per well in a P12 plate. Recombinant mouse Fms-related tyrosine kinase 3 ligand (FLT3L) obtained from Miltenyi Biotec was added to cultures at 200ng / mL. Differentiated cells were used for subsequent assays on day 8. The efficiency ofsf-5700344Docket No.: 16553-20009.40 differentiation was monitored by flow cytometry using BD Symphony A3, and CD11c+MHC- II+ cells were routinely above 80% of living cells. For each experiment, 5 mice are used to collect bone marrow and to generate DCs.
[0112] Glycerolipid preparation. 22:0 LysoPC (1-behenoyl-2-hydroxy-sn-glycero-3- phosphocholine) liquid stocks were formulated at 650μg / mL lipid by mixing a lyophilized stock with PBS. DGP (1-docosyl-sn-glycerol-3-phosphate) liquid stocks were formulated at 650μg / mL lipid by mixing a lyophilized stock with a Kolliphor P407 (KP407) solution at 1000rpm for 1hr at room temperature. A 10X PBS solution was then added to the DGP / KP407 solution, which was mixed for an additional 30min at room temperature to produce an isotonic DGP / 4% KP407 stock solution. Lipid stocks were further diluted in PBS before treating cells.
[0113] Hyperactivation of murine bone marrow-derived FLT3L-DCs. BMDCs were harvested on day 8 post differentiation, washed with PBS and re-plated in FLT3L-containing I10 media at a concentration of 2x105cells / mL. Cells were primed with or without 1μg / mL R848 (final) then treated with or without a hyperactivating lipid (or vehicle control). To hyperactivate cells in the presence of a bystander antigen, chicken egg white ovalbumin (OVA) or bovine serum albumin (BSA) was added using a serial 2-fold dilution starting from 1000μg / mL. The OVA used was the EndoFit™ ovalbumin from InvivoGen and the BSA used was obtained from Thermo Scientific. Forty-eight hours post stimulation, supernatants were collected for cytokine measurement. Viability was measured using the CellTiter-Glo assay (Promega), which measures ATP content of cells. Fifty microliters of CellTiter-Glo reagent were added to 50μL of cells. Luminescence was quantified on a SpectraMax m5e plate reader using an integration time of 500 milliseconds. Viability data were set relative to control conditions where cells were treated with R848. IL-1ȕ and TNFĮ cytokine secretion were measured using sandwich ELISAs (Invitrogen).
[0114] Ex vivo whole tumor lysate preparation. Syngeneic whole tumor lysates (WTL) were prepared from tumor explants of unimmunized tumor-bearing mice. Briefly, tumors from unimmunized mice bearing a 10-12 mm size tumor were mechanically disaggregated using gentleMACS™ dissociator (Miltenyi Biotec) and enzymatically digested using the Tumor Dissociation Kit (Miltenyi Biotec) following the manufacturer’s protocol. After digestion, tumor cell suspensions were washed with PBS and passed through 70μm and then 30μm filters. Tumor cells were then counted and resuspended at 2x107cells / ml then lysed by 3-4 cycles of freeze-sf-5700344Docket No.: 16553-20009.40 thawing. The lysed cells were further disrupted by repeatedly passing the material through 18G, then 21G, and finally 25G needles. Lysate was filtered again through 70μm and then 30μm filers and stored in aliquots at -80°C until use. Protein quantification in the lysates was performed using the BCA assay. WTL were used for immunotherapy at a concentration equivalent to 50μg per mouse.
[0115] Immunotherapy. C57BL / 6J mice were injected subcutaneously with 50,000 LLC1 or B16F10 cells on the right upper back. LLC1 is a murine Lewis lung carcinoma cell line. B16F10 is a murine melanoma cell line. Four or seven days later, mice were either injected subcutaneously (SC) with PBS or immunized distally from the tumor injection site with 50μg of WTL derived from syngeneic tumors in combination with the hyperactivating stimuli (R848 100μg / mouse, R848100μg / mouse + 22:0 LysoPC 65μg / mouse, or R848100μg / mouse + DGP 65μg / mouse) alone or in combination with a bystander antigen. The bystander antigens tested included OVA (EndoFit™ ovalbumin from InvivoGen) and COVID-19 (recombinant SARS- CoV-2 spike His-tag from R& D Systems, Catalog No. 10549-CV). The amino acid sequence of OVA is set forth as SEQ ID NO:1. The amino acid sequence of the recombinant SARS-CoV-2 spike protein (without the His-tag) is set forth as SEQ ID NO:2. Mice received 4 boost injections with PBS or the same doses of WTL with hyperactivating stimuli, and with or without bystander antigen.
[0116] Ex vivo restimulation. Survivor mice that had been immunized with a composition comprising both WTL and COVID-19 spike protein were euthanized 50 days post LLC1 injection. CD4+ and CD8+ T cells were isolated from the draining lymph nodes of LLC1- survivor mice by magnetic enrichment using mouse anti-CD4 and anti-CD8 beads following the manufacturer’s protocol (Miltenyi). Post-enrichment purity was found to be above 80%. CD4+ and CD8+ T cells were then co-cultured for 5 days with naïve DCs loaded (or not) with 100μg of WTL or 20μg of COVID-19 spike protein to assess antigen-specific T cell responses. Supernatants were collected, and IFN-gamma cytokine secretion was measured by ELISA. Results
[0117] Bystander antigens enhance anti-tumor immunity mediated by immunotherapy with R848+WTL+22: LysoPC. C57BL / 6J mice injected with LLC1 cells (lung carcinoma model) were subjected to one of three different immunotherapy regimens administered by SCsf-5700344Docket No.: 16553-20009.40 injection 4 days later: i) control: PBS; ii) whole tumor lysate (WTL) in combination with the TLR7 agonist R848 plus the hyperactivating lipid 22:0 LysoPC; and iii) WTL in combination with R848, 22:0 LysoPC and the bystander antigen ovalbumin (OVA). Immunized mice then received four boost injections on Days 12, 16, 20 and 28 post tumor cell inoculation. Tumor growth and survival were measured every two days. As shown in FIG.1A, immunization with WTL+R848+22:0 LysoPC did not induce a potent anti-tumor response in all mice as evidenced by more than 60% of mice succumbing to tumor growth by day 60. Interestingly, 100% of mice injected with WTL+OVA in combination with R848+22:0 LysoPC remained alive at day 60. Tumor size over time is shown in FIG. 1B.
[0118] Similarly, C57BL / 6J mice injected with B16F10-derived tumors (melanoma model) were not immunized (PBS only) or were subjected to one of three different immunotherapy regimens administered by SC injection 7 days later: i) control: PBS; ii) WTL in combination with R848; iii) WTL in combination with R848 and 22:0 LysoPC; and iv) WTL in combination with R848, 22:0 LysoPC and the bystander antigen OVA. Immunized mice then received 4 boost injections on Days 11, 14, 18 and 21 post tumor cell inoculation. As in the LLC1 model, the addition of OVA to the WTL induced stronger anti-tumor immunity as assessed by survival (FIG.5) and tumor-size.
[0119] Bystander antigens do not act as a hyperactivating lipid carrier. To assess whether the bystander antigen acts as a carrier of 22:0 LysoPC, which in turn enhances the hyperactivation of DCs at the injection site, the effect of increasing concentrations of bystander antigen on IL-^ȕ^VHFUHWLRQ^E\^'&V^ZDV^DVVHVVHG. Two different bystander antigens were tested: ovalbumin (OVA) and bovine serum albumin (BSA). FLT3L-DCs were cultured with 1μg / ml of R848 and 82μM of 22:0 lysoPC in the presence of a serial dilution of OVA or BSA. The concentration of BSA and OVA tested did not affect the extent of DC hyperactivation as determined by measuring IL-^ȕ^VHFUHWLRQ^E\^DCs (FIG. 2). Thus, the exemplary bystander antigens (OVA and BSA) do not enhance DC hyperactivation.
[0120] Bystander antigens enhance anti-tumor immunity mediated by immunotherapy with R848+WTL+DGP. C57BL / 6J mice injected subcutaneously with LLC1 cells (lung carcinoma model) were not immunized or were subjected to one of two different immunotherapy regimens administered by SC injection 7 days later: i) control: unimmunized ii) WTL insf-5700344Docket No.: 16553-20009.40 combination with R848 and 1-docosyl-sn-glycerol-3-phosphate (DGP); and iii) WTL in combination with R848, DGP and a bystander antigen (COVID-19 recombinant spike protein). Immunized mice then received four boost injections on Days 11, 14, 18 and 21 post tumor inoculation. As shown in FIG. 3A, immunization with WTL+R848+DGP in the presence or absence COVID-19 antigen induced strong anti-tumor responses. While 100% survival was not observed in either study group, the majority of mice injected with WTL or WTL+COVID-19 in combination with R848+DGP remained alive at day 50. Tumor size over time is shown in FIG.3B.
[0121] Immunization with WTL in combination with a bystander antigen induces antigen-specific T cell responses. C57BL / 6J mice injected subcutaneously with LLC1 cells (lung carcinoma model) were not immunized or were subjected to one of three different immunotherapy regimens administered by SC injection 7 days later: i) control: unimmunized, ii) WTL in combination with LPS and PGPC, iii) WTL in combination with R848 and 1-docosyl- sn-glycerol-3-phosphate (DGP); and iv) WTL in combination with R848, DGP and a bystander antigen (COVID-19 recombinant spike protein). Immunized mice then received four boost injections on Days 11, 14, 18 and 21 post tumor inoculation. 50 days post LLC1 injection, survivor mice were euthanized to assess T cell responses in draining lymph nodes of the skin. To this end, CD4+ and CD8+ T cells were enriched using mouse anti-CD4 and anti-CD8 beads. T cells were then co-cultured with DCs that were loaded with either COVID-10 spike protein, or WTL. Alternatively, T cells were co-cultured with naïve DCs that were not loaded with any antigen. Five days post co-culture, antigen-induced secretion of IFN-gamma in the supernatant as a result of T cell activation / memory T cell reactivation was measured. Mice immunized with a composition comprising both WTL and COVID-19 spike protein induced higher IFN-gamma responses when CD8+ T cells (FIG. 4A) or CD4+ T cells (FIG. 4B) were restimulated in vitro in the presence of DCs loaded with WTL or COVID-19 spike protein. In contrast, T cells that were co-cultured with DCs that were not loaded with an antigen did not secrete high levels of IFN-gamma. These data indicate that the immunization with a composition comprising both WTL and COVID-19 spike protein induces antigen-specific CD4+ and CD8+ T cell responses against both antigens (the WTL and the bystander antigen, herein COVID spike protein).sf-5700344Docket No.: 16553-20009.40 Example 2: Antigen-Specific T-cell Responses Elicited by Immunization with a Whole Tumor Lysate in Combination With a Bystander Antigen
[0122] This example describes antigen-specific recall responses of splenocytes of immunized mice. Material and Methods
[0123] Ex vivo whole tumor lysate preparation. Syngeneic whole tumor lysates (WTL) were prepared from tumor explants of unimmunized LLC1 tumor-bearing mice. LLC1 is a murine Lewis lung carcinoma cell line. Briefly, tumors from unimmunized mice bearing a 10- 12 mm size tumor were mechanically disaggregated using gentleMACS™ dissociator (Miltenyi Biotec) and enzymatically digested using the Tumor Dissociation Kit (Miltenyi Biotec) following the manufacturer’s protocol. After digestion, tumor cell suspensions were washed with PBS and passed through 70μm and then 30μm filters. Tumor cells were then counted and resuspended at 2x107cells / ml then lysed by 3-4 cycles of freeze-thawing. The lysed cells were further disrupted by repeatedly passing the material through 18G, then 21G, and finally 25G needles. Lysate was filtered again through 70μm and then 30μm filers and stored in aliquots at - 80°C until use. Protein quantification in the lysates was performed using the BCA assay. WTL were used at a concentration equivalent to 220μg per mouse.
[0124] Immunizations. Mice were either injected subcutaneously (SC) with PBS or immunized with 220μg of WTL derived from syngeneic LLC1 tumors in combination with the hyperactivating stimuli (R84850μg / mouse + DGP 100μg / mouse) alone or in combination with a bystander antigen (day 0). In this study, two bystander antigens were employed at 20μg / mouse: recombinant Influenza A Virus H1N1 hemagglutinin (HA) protein from R & D Systems (Catalog No. 10973-HA); and recombinant SARS-CoV-2 spike protein from R & D Systems (Catalog No. 10549-CV). The amino acid sequence of HA is set forth as SEQ ID NO:3, and the amino acid sequence of spike (without the His-tag) is set forth as SEQ ID NO:2. Mice received 2 boost injections with PBS or the same doses of WTL with hyperactivating stimuli, and with or without bystander antigen every 7 days (day 7 and day 14).
[0125] Ex vivo restimulation. On day 21, spleens were harvested and digested using the spleen dissociation kit following the manufacturer’s protocol (Miltenyi Biotec). To assess antigen-specific T cell responses, single cell suspensions from the spleen of each mouse weresf-5700344Docket No.: 16553-20009.40 restimulated for 72 hours with 500μg of WTL or SARS-CoV-2 Spike PepTivator (Miltenyi Biotec Catalogue No.130-129-712). The Spike PepTivator is a pool of peptides, consisting mainly of 15-mer sequences with 11 amino acid overlaps covering the spike protein. Supernatants were collected, and IFN-gamma cytokine secretion was measured by ELISA. Results
[0126] Immunization with WTL in combination with a bystander antigen induces antigen-specific T-cell responses. C57BL / 6J mice were either injected on Day 0 with PBS or were immunized by SC injection with WTL in combination with R848 and DGP; or WTL in combination with R848, DGP and a bystander antigen (spike protein or HA). Immunized mice received booster injections on Days 7, and 14. On Day 21, T-cell responses in the spleen were assessed. Splenocytes were either left unstimulated or restimulated with either 10μg / mL SARS- CoV-2 Spike PepTivator, or 500μg / mL of WTL. After culturing the splenocytes for 72 hours, antigen-induced secretion of IFN-gamma in the supernatant was measured to assess T-cell activation / memory T-cell reactivation. Mice immunized with a composition comprising WTL and the hyperactivating stimuli in the presence or absence of bystander antigens induced high levels of IFN-gamma secretion when their splenocytes were restimulated with WTL, as compared to mice injected with PBS (FIG.6A). Notably, no significant difference was observed when mice were immunized with WTL alone or in combination with bystander antigen indicating that the addition of bystander antigen did not interfere with the generation of antigen- specific T-cell responses against WTL. Furthermore, when splenocytes of study mice were restimulated with Spike PepTivator, significantly higher levels of IFN-gamma were only secreted from splenocytes of mice that were immunized with WTL, hyperactivating stimuli and spike protein (WTL+R848+DGP+spike) as compared to splenocytes of mice injected with PBS, or mice injected with WTL and hyperactivating stimuli alone (WTL+R848+DGP) or in combination with HA protein (WTL+R848+DGP+HA protein) (FIG. 6B). These data indicate that immunization with a composition comprising both WTL and spike protein as a bystander antigen induces antigen-specific T cell response against both antigens (WTL and bystander antigen).sf-5700344Docket No.: 16553-20009.40 SEQUENCES SEG ID NO:1 >Gallus gallus ovalbumin (OVA) 1 mgsigaasme fcfdvfkelk vhhanenify cpiaimsala mvylgakdst rtqinkvvrf 61 dklpgfgdsi eaqcgtsvnv hsslrdilnq itkpndvysf slasrlyaee rypilpeylq 121 cvkelyrggl epinfqtaad qarelinswv esqtngiirn vlqpssvdsq tamvlvnaiv 181 fkglwekafk dedtqampfr vteqeskpvq mmyqiglfrv asmasekmki lelpfasgtm 241 smlvllpdev sgleqlesii nfekltewts snvmeerkik vylprmkmee kynltsvlma 301 mgitdvfsss anlsgissae slkisqavha ahaeineagr evvgsaeagv daasvseefr 361 adhpflfcik hiatnavlff grcvsp SEQ ID NO:2 >SARS-CoV-2 spike protein vnltt rtqlppaytn sftrgvyypd kvfrssvlhs tqdlflpffs 61 nvtwfhaihv sgtngtkrfd npvlpfndgv yfasteksni irgwifgttl dsktqslliv 121 nnatnvvikv cefqfcndpf lgvyyhknnk swmesefrvy ssannctfey vsqpflmdle 181 gkqgnfknlr efvfknidgy fkiyskhtpi nlvrdlpqgf saleplvdlp iginitrfqt llalhrsylt pgdsssgwta gaaayyvgyl qprtfllkyn engtitdavd caldplsetk ctlksftvek giyqtsnfrv qptesivrfp nitnlcpfge vfnatrfasv yawnrkrisn 361 cvadysvlyn sasfstfkcy gvsptklndl cftnvyadsf virgdevrqi apgqtgkiad 421 ynyklpddft gcviawnsnn ldskvggnyn ylyrlfrksn lkpferdist eiyqagstpc 481 ngvegfncyf plqsygfqpt ngvgyqpyrv vvlsfellha patvcgpkks tnlvknkcvn 541 fnfngltgtg vltesnkkfl pfqqfgrdia dttdavrdpq tleilditpc sfggvsvitp 601 gtntsnqvav lyqdvnctev pvaihadqlt ptwrvystgs nvfqtragcl igaehvnnsy 661 ecdipigagi casyqtqtns pSraSsvasq siiaytmslg aensvaysnn siaiptnfti 721 svtteilpvs mtktsvdctm yicgdstecs nlllqygsfc tqlnraltgi aveqdkntqe vfaqvkqiyk tppikdfggf nfsqilpdps kpskrsfied llfnkvtlad agfikqygdc lgdiaardli caqkfngltv lpplltdemi aqytsallag titsgwtfga gaalqipfam qmayrfngig vtqnvlyenq klianqfnsa igkiqdslss tasalgklqd vvnqnaqaln tlvkqlssnf gaissvlndi lsrldPPeae vqidrlitgr lqslqtyvtq qliraaeira sanlaatkms ecvlgqskrv dfcgkgyhlm sfpqsaphgv vflhvtyvpa qeknfttapa ichdgkahfp regvfvsngt hwfvtqrnfy epqiittdnt fvsgncdvvi givnntvydp lqpeldsfke eldkyfknht spdvdlgdis ginasvvniq keidrlneva knlneslidl qelgkyeqyi k SEQ ID NO:3 >Influenza A virus H1N1 hemagglutinin 1 mkailvvlly tfatanadtl cigyhannst dtvdtvlekn vtvthsvnll edkhngklck 61 lrgvaplhlg kcniagwilg npeceslsta sswsyivetp ssdngtcypg dfidyeelre 121 qlssvssfer feifpktssw pnhdsnkgvt aacphagaks fyknliwlvk kgnsypklsk 181 syindkgkev lvlwgihhps tsadqqslyq nadayvfvgs sryskkfkpe iairpkvrxx 241 egrmnyywtl vepgdkitfe atgnlvvpry afamernags giiisdtpvh dcnttcqtpk 301 gaintslpfq nihpitigkc pkyvkstklr latglrnips iqsrglfgai agfieggwtg 361 mvdgwygyhh qneqgsgyaa dlkstqnaid eitnkvnsvi ekmntqftav gkefnhlekr 421 ienlnkkvdd gfldiwtyna ellvllener tldyhdsnvk nlyekvrsql knnakeigng 481 cfefyhkcdn tcmesvkngt ydypkyseea klnreeidgv klestriyqi laiystvass 541 lvlvvslgai sfwmcsngsl qcricisf-5700344
Claims
Docket No.: 16553-20009.40 CLAIMS We claim:
1. An immunogenic composition comprising a tumor cell lysate and an isolated bystander antigen, wherein the tumor cell lysate is prepared from a tumor of a mammalian subject, the isolated bystander antigen comprises a polypeptide that is heterologous to the mammalian subject.
2. The composition of claim 1, wherein the composition further comprises a pathogen recognition receptor (PRR) agonist.
3. The composition of claim 1, wherein the composition further comprises a lipid, wherein the lipid comprises a glycerolipid or a phospholipid analog.
4. The composition of claim 1, wherein the immunogenic composition further comprises a lipid and a PRR agonist, wherein the lipid comprises a glycerolipid or a phospholipid analog.
5. The composition of any one of claims 1-4, wherein the bystander antigen comprises a mammalian antigen, an avian antigen, a reptilian antigen, or an amphibian antigen.
6. The composition of any one of claims 1-4, wherein the bystander antigen comprises a mammalian antigen, and wherein the mammalian antigen is of different taxonomic genus, family, or order than the mammalian subject.
7. The composition of any one of claims 1-4, wherein the bystander antigen comprises a microbial antigen.
8. The composition of claim 7, wherein the microbial antigen comprises one or more of a viral antigen, a bacterial antigen, a protozoan antigen, and a fungal antigen.
9. The composition of claim 7, wherein the microbial antigen comprises a viral antigen.sf-5700344Docket No.: 16553-20009.40 10. The composition of claim 9, wherein the viral antigen comprises an inactivated, whole virus.
11. The composition of any one of claims 1-9, wherein the bystander antigen comprises a synthetic or recombinant polypeptide.
12. The composition of any one of claims 1-9, wherein the bystander antigen comprises a native polypeptide.
13. The composition of any one of claims 1-12, wherein the polypeptide is from about 20 to about 2000 amino acids in length, optionally from about 30 to about 1700 amino acids in length, optionally from about 40 to about 1600 amino acids in length, optionally from about 50 to about 1500 amino acids length, optionally from about 60 to about 1400 amino acids length, optionally from about 70 to about 1300 amino acids length, optionally from about 80 to about 1200 amino acids length, optionally from about 90 to about 1100 amino acids length, optionally from about 100 to about 1000 amino acids length.
14. The composition of any one of claims 3-13, wherein the lipid comprises a glycerolipid, optionally wherein the glycerolipid comprises a C13-C24 acyl chain or a C13-C24 alkyl chain, optionally wherein the glycerolipid comprises a C19-C22 acyl chain or a C19-C22 alkyl chain.
15. The composition of claim 14, wherein the glycerolipid is an isolated ether lipid (ETL).
16. The composition of claim 15, wherein the ETL is an isolated ether phospholipid (ETPL).
17. The composition of claim 16, wherein the ETPL comprises 1-docosyl-sn- glycerol-3-phosphate (DGP), or a pharmaceutically acceptable salt thereof.
18. The composition of claim 16, wherein the ETPL comprises 1-docosyl-sn- glycerol-3-phosphocholine (DGPC), or a pharmaceutically acceptable salt thereof.sf-5700344Docket No.: 16553-20009.40 19. The composition of any one of claims 3-13, wherein the lipid comprises a phospholipid analog, optionally wherein the phospholipid analog comprises a C13-C24 acyl chain or a C13-C24 alkyl chain, optionally wherein the phospholipid analog comprises a C16- C18 acyl chain or a C16-C18 alkyl chain.
20. The composition of claim 19, wherein the phospholipid analog is selected from the group consisting of edelfosine, miltefosine and perifosine.
21. The composition of claim 14, wherein the glycerolipid comprises an isolated lysophosphatidylcholine (LPC) having a single acyl chain.
22. The composition of claim 21, wherein the acyl chain is a C22 acyl chain.
23. The composition of claim 22, wherein the acyl chain is fully saturated.
24. The composition of claim 23, wherein the isolated LPC comprises 1-behenoyl-2- hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)].
25. The composition of claim 14, wherein the glycerolipid comprises oxPAPC or an isolated species of oxPAPC.
26. The composition of claim 25, wherein the species of oxPAPC comprises one or more of PGPC, HOdiA-PC, KOdiA-PC, HOOA-PC, and KOOA-PC.
27. The composition of claim 25, wherein the species of oxPAPC comprises PGPC.
28. The composition of any one of claims 1-27, wherein the composition does not comprise LPS or MPLA.
29. The composition of any one of claims 1-28, wherein the PRR agonist is an agonist of a toll-like receptor (TLR), an agonist of a NOD-like receptor (NLR), an agonist of a RIG-I- like receptor (RLR), or an agonist of a C-type lectin receptor (CLR).
30. The composition of claim 29, wherein PRR agonist comprises a TLR7 / 8 agonist.sf-5700344Docket No.: 16553-20009.40 31. The composition of claim 30, wherein the TLR7 / 8 agonist is a small molecule with a molecule weight of 900 daltons or less.
32. The composition of claim 31, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound.
33. The composition of claim 32, wherein the TLR7 / 8 agonist comprises resiquimod (R848).
34. The composition of claim 32 or claim 33, wherein the TLR7 / 8 agonist does not inhibit NLR family pyrin domain containing 3 (NLRP3).
35. The composition of claim 29, wherein the PRR agonist is an agonist of a cytosolic DNA sensor (CDS) or a stimulator of IFN genes (STING).
36. The composition of claim 29, wherein the PRR agonist comprises one or more of R848, TL8-506, LPS, Pam2CSK4, and ODN 2336.
37. The composition of any one of claims 4-13, wherein the immunogenic composition comprises a glycerolipid comprising 1-behenoyl-2-hydroxy-sn-glycero-3- phosphocholine [LPC(22:0)], and the TLR7 / 8 agonist comprises resiquimod (R848).
38. The composition of any one of claims 4-13, wherein the immunogenic composition comprises a glycerolipid comprising 1-docosyl-sn-glycerol-3-phosphate (DGP), or a pharmaceutically acceptable salt thereof, and the TLR7 / 8 agonist comprises resiquimod (R848).
39. The composition of any one of claims 4-13, wherein the immunogenic composition comprises a glycerolipid comprising 1-docosyl-sn-glycerol-3-phosphocholine (DGPC), or a pharmaceutically acceptable salt thereof, and the TLR7 / 8 agonist comprises resiquimod (R848).
40. The composition of any one of claims 4-13, wherein the immunogenic composition comprises a phospholipid analog comprising edelfosine, miltefosine or perifosine, and the TLR7 / 8 agonist comprises resiquimod (R848).sf-5700344Docket No.: 16553-20009.40 41. The composition of any one of claims 1-40, wherein the immunogenic composition further comprises a surfactant.
42. The composition of claim 41, wherein the surfactant comprises a non-ionic surfactant.
43. The composition of claim 42, wherein the non-ionic surfactant comprises an ethylene oxide-propylene oxide copolymer.
44. The composition of claim 42, wherein the non-ionic surfactant comprises one or more of Poloxamer 407, Poloxamer 188, and P123.
45. The composition of claim 42, wherein the non-ionic surfactant comprises Poloxamer 407.
46. The composition of any one of claims 42-45, wherein the non-ionic surfactant is present in an amount of about 0.5% to about 50% (w / w), optionally in an amount of about 2.5% to about 25% (w / w), optionally in an amount of about 5% to about 20% (w / w), optionally in an amount of about 10% to about 15% (w / w).
47. The composition of any one of claims 1-46, wherein the immunogenic composition further comprises a pharmaceutically acceptable excipient.
48. The composition of any one of claims 1-47, wherein the immunogenic composition further comprises an adjuvant, optionally wherein the adjuvant comprises an aluminum salt adjuvant, a squalene-in-water emulsion, a saponin, or combinations thereof.
49. The composition of any one of claims 1-48, wherein the tumor cell lysate is a whole tumor lysate.
50. The composition of any one of claims 1-49, wherein cells from the tumor are not contacted with the bystander antigen or cultured in vitro prior to preparation of the tumor cell lysate.sf-5700344Docket No.: 16553-20009.40 51. The composition of any one of claims 1-50, wherein the tumor cell lysate was prepared from a sample of the tumor obtained through biopsy of the tumor or surgical excision of the tumor.
52. The composition of claim 51, wherein the sample was subjected to mechanical dissociation and enzymatic digestion to produce a tumor cell suspension prior to preparation of the tumor cell lysate.
53. The composition of claim 52, wherein the tumor cells were lysed by one or more freeze-thaw cycles.
54. The composition of any one of claims 1-53, wherein the tumor is a solid tumor, optionally wherein the solid tumor is a melanoma, a carcinoma, or a sarcoma.
55. A method of stimulating an anti-tumor immune response, the method comprising administering an effective amount of the immunogenic composition of any one of claims 1-54 to the mammalian subject to stimulate an immune response against the tumor cell lysate and the bystander antigen, optionally wherein the immune response is reactive with cells of the subject’s tumor.
56. A method of treating cancer, the method comprising administering an effective amount of the immunogenic composition of any one of claims 1-54 to the mammalian subject to treat the cancer.
57. A method of inhibiting abnormal cell proliferation, comprising administering an effective amount of the immunogenic composition of any one of claims 1-54 to the mammalian subject to inhibit abnormal cell proliferation.
58. A method of treating or preventing an infectious disease, comprising administering an effective amount of the immunogenic composition of any one of claims 7-54 to the mammalian subject to treat or prevent the infectious disease, wherein the microbial antigen is of the causative agent of the infectious disease.sf-5700344Docket No.: 16553-20009.40 59. Use of the immunogenic composition of any one of claims 1-54 for inducing an immune response against the tumor cell lysate and the bystander antigen in the mammalian subject.
60. Use of the immunogenic composition of any one of claims 1-54 for treating cancer in the mammalian subject.
61. Use of the immunogenic composition of any one of claims 1-54 for inhibiting abnormal cell proliferation in the mammalian subject.
62. Use of the immunogenic composition of any one of claims 7-54 for treating or preventing an infectious disease in the mammalian subject, wherein the microbial antigen is of the causative agent of the infectious disease.
63. The composition, method or use of any one of claims 1-62, wherein the mammalian subject is a human subject.
64. A method of preparing an immunogenic composition, the method comprising: contacting a tumor cell lysate, prepared from a tumor of a mammalian subject, with an isolated bystander antigen to obtain the immunogenic composition, wherein the bystander antigen comprises a polypeptide that is heterologous to the mammalian subject.
65. The method of claim 64, wherein the contacting step further comprises contacting the tumor cell lysate with an isolated glycerolipid or phospholipid analog, and / or a pathogen recognition receptor (PRR) agonist.
66. A method of preparing an immunogenic composition, the method comprising: a) obtaining a tumor cell suspension from a tumor of a mammalian subject; b) lysing cells from the tumor cell suspension to obtain a tumor cell lysate; and c) contacting the tumor cell lysate with an isolated bystander antigen, an isolated glycerolipid or phospholipid analog, and a pathogen recognition receptor (PRR) agonist to obtain the immunogenic composition, wherein the bystander antigen comprises a polypeptide that is heterologous to the mammalian subject.sf-5700344Docket No.: 16553-20009.40 67. The method of claim 66, wherein the cells are lysed in step b) by one or more freeze-thaw cycles.
68. The method of claim 66 or claim 67, wherein the tumor cell suspension was prepared from a sample of the tumor obtained through biopsy of the tumor or surgical excision of the tumor.
69. The method of claim 68, wherein the sample was subjected to mechanical dissociation and enzymatic digestion to produce the tumor cell suspension.
70. The method of any one of claims 64-69, wherein the tumor is a solid tumor, optionally wherein the solid tumor is a melanoma, a carcinoma, or a sarcoma.
71. The method of any one of claims 64-69, wherein the tumor is a lymphoma.
72. The method of any one of claims 64-71, wherein the bystander antigen comprises a mammalian antigen, an avian antigen, a reptilian antigen, or an amphibian antigen.
73. The method of claim 72, wherein the bystander antigen comprises a mammalian antigen, and wherein the mammalian antigen is of different taxonomic genus, family, or order than the mammalian subject.
74. The method of any one of claims 64-71, wherein the bystander antigen comprises a microbial antigen.
75. The method of claim 74, wherein the microbial antigen comprises one or more of a viral antigen, a bacterial antigen, a protozoan antigen, and a fungal antigen.
76. The method of claim 74, wherein the microbial antigen comprises a viral antigen.
77. The method of claim 76, wherein the viral antigen comprises an inactivated, whole virus.
78. The method of any one of claims 64-77, wherein the bystander antigen comprises a synthetic or recombinant polypeptide.sf-5700344Docket No.: 16553-20009.40 79. The method of any one of claims 64-77, wherein the bystander antigen comprises a native polypeptide.
80. The method of any one of claims 64-79, wherein the polypeptide is from about 8 to about 8000 amino acids in length, optionally from about 20 to about 2000 amino acids in length, optionally from about 30 to about 1700 amino acids in length, optionally from about 40 to about 1600 amino acids in length, optionally from about 50 to about 1500 amino acids length, optionally from about 60 to about 1400 amino acids length, optionally from about 70 to about 1300 amino acids length, optionally from about 80 to about 1200 amino acids length, optionally from about 90 to about 1100 amino acids length, optionally from about 100 to about 1000 amino acids length.
81. The method of any one of claims 65-80, wherein the contacting step comprises contacting the tumor cell lysate with an isolated bystander antigen, an isolated glycerolipid, and a pathogen recognition receptor (PRR) agonist to obtain the immunogenic composition.
82. The method of claim 81, wherein the isolated glycerolipid comprises an isolated lysophosphatidylcholine (LPC) having a single C19-C22 acyl chain.
83. The method of claim 82, wherein the isolated LPC comprises 1-behenoyl-2- hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)].
84. The method of claim 81, wherein the isolated glycerolipid comprises an isolated ether phospholipid (ETPL).
85. The method of claim 84, wherein the ETPL comprises 1-docosyl-sn-glycerol-3- phosphate (DGP), or a pharmaceutically acceptable salt thereof.
86. The method of claim 84, wherein the ETPL comprises 1-docosyl-sn-glycerol-3- phosphocholine (DGPC), or a pharmaceutically acceptable salt thereof.
87. The method of any one of claims 65-80, wherein the contacting step comprises contacting the tumor cell lysate with an isolated bystander antigen, an isolated phospholipidsf-5700344Docket No.: 16553-20009.40 analog, and a pathogen recognition receptor (PRR) agonist to obtain the immunogenic composition.
88. The method of claim 87, wherein the phospholipid analog is selected from the group consisting of edelfosine, miltefosine and perifosine.
89. The method of any one of claims 64-88, wherein the PRR agonist is an agonist of a toll-like receptor (TLR), an agonist of a NOD-like receptor (NLR), an agonist of a RIG-I-like receptor (RLR), or an agonist of a C-type lectin receptor (CLR).
90. The method of claim any one of claims 64-88, wherein PRR agonist comprises a TLR7 / 8 agonist.
91. The method of claim 90, wherein the TLR7 / 8 agonist is a small molecule with a molecule weight of 900 daltons or less.
92. The method of claim 91, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound.
93. The method of claim 92, wherein the TLR7 / 8 agonist comprises resiquimod (R848).
94. The method of any one of claims 64-93, wherein the tumor cell lysate is a whole tumor lysate.
95. The method of any one of claims 64-94, wherein cells from the tumor are not contacted with the bystander antigen or cultured in vitro prior to preparation of the tumor cell lysate in step b).
96. An immunogenic composition prepared by the method of any one of claims 64- 95.
97. A method of eliciting an anti-cancer immune response, the method comprising: administering to a mammalian subject with cancer an effective amount of the immunogenic composition of claim 95.sf-5700344Docket No.: 16553-20009.40 98. The method of claim 97, wherein the anti-cancer immune response comprises a cellular immune response.
99. The method of claim 98, wherein the cellular immune response comprises tumor cell lysate-induced interferon-gamma secretion by CD8+ and / or CD4+ T lymphocytes.
100. The method of any one of clams 97-99, further comprising administering to the subject an effective amount of an additional therapeutic agent.
101. The method of claim 100, wherein the additional therapeutic agent comprises one or more of the group consisting of an immune checkpoint inhibitor, an antineoplastic agent, and radiation therapy.
102. Invention, in any form of its embodiments or in any claim category applicable for claiming, e.g., product or process or use encompassed by the subject-matter initially described, disclosed or illustrated in the patent application.sf-5700344
Citation Information
Patent Citations
Mixture of tubercle bacillus HSP and tumor lysate
CN101637608A
Compositions and methods for activating antigen presenting cells with chimeric poliovirus
US11331343B2
Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
US9764014B2
Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy
WO2021102058A1
Hyperactivators of mammalian dendritic cells
WO2022221827A2
